

FESTIVAL OF BIOLOGICS

Tuesday 9th November – Thursday 11th November 2021

Basel Congress Centre, Basel, Switzerland

Presents



Contents

European Antibody Congress	3
Advisory Board	3
Confirmed speakers:	4
Day 1 – Tuesday 9th November	7
Day 2 – Wednesday 10th November	12
Day 3 – Thursday 11th November	17
World Immunotherapy Congress	20
Advisory Board:	20
Confirmed speakers	21
Day 1 – Tuesday 9th November	24
Day 2 – Wednesday 10th November	28
Day 3 – Thursday 11th November	33
World Biosimilar Congress	35
Advisory Board	35
Confirmed speakers	36
Day 1 - Tuesday 9th November	37
Day 2 – Wednesday 10th November	41
Day 3 – Thursday 11th November	46

FESTIVAL OF
BIOLOGICS



European Antibody Congress

Basel Congress Center, 9th-11th November 2021

Advisory Board

Ahuva Nissim, Professor in Antibody and Therapeutic Engineering Biochemical Pharmacology, William Harvey Research Institute, **Queen Mary University**

Alain Beck, Senior Director, Biologics CMC and Developability, **Pierre Fabre**, Associate Editor, *mAbs*

Christian Klein, Head of Oncology Programmes, Department Head Cancer Immunotherapy, **Roche Innovation Center Zurich**, **Roche Pharma Research and Early Development**

John Delaney, Executive Director of Research, **Amgen**

Thomas Huber, Head of Research, **Almirall**

René Assenberg, Associate Director, Analytical Development, **Janssen Biologics**

Confirmed speakers:

Aaron Sato, CSO, **Twist Bioscience**

Achim Doerner, Principal Researcher, **Merck Healthcare KGaA, Darmstadt**

Alain Beck, Senior Director, Biologics CMC and Developability, **Pierre Fabre**, Associate Editor, *mAbs*

Alain Wagner, Research Director and Head, **BioFunctional Chemistry Lab**

Alexander Baumann, Head of European Business Development, **DiscoverX Products, Eurofins DiscoverX products**

Alissa Hummer, PhD Student, **University of Oxford**

Anders Pedersen, Medical Lead in Global Clinical Development, **Almirall**

Andrea Marschall, Post-Doc, **Brandeis University**

Andreas Herrmann, CEO, **Corat Therapeutics**

Andreas Plueckthun, Professor of Biochemistry, Director, Department of Biochemistry, **University of Zurich**

Andrew Goodearl, Senior Director, **Abbvie Bioresearch Center**

Anne Ljungars, Senior Scientist, **Technical University of Denmark**

Annick de Vries, PhD. Director Pharma & Biotech Services, **Sanquin Health Solutions, Sanquin**

Armin Sepp, Scientific Leader and GSK Associate Fellow, **GSK**

Arne Skerra, Professor, Biological Chemistry, **TU Munich & XL-protein**

Audrey Desgranges, Chief Operating Officer, **McSAF Inside Oncology**

Benjami Oller-Salvia, Assistant Professor, IQS School of Engineering, **Ramon Llull University**

Bernard Maillere, Head of laboratory, CEA, Head, Immunology and Biotherapies, **Université Paris-Sud**

Bernard Vanhove, CSO, **Xenothera**

Caroline Barelle, CEO & Co-Founder, **Elasmogen**

Carlo Boutton, Global Head Innovation, Large Molecule Research Platform, **Sanofi**

Chris Scott, Professor, **Queen's University Belfast**

Christian Klein, Head of Oncology Programmes, Department Head Cancer Immunotherapy, **Roche Innovation Center Zurich, Roche Pharma Research and Early Development**

Christoph Merten, Professor, Laboratory for Biomedical Microfluidics, Swiss Federal Institute of Technology Lausanne (EPFL)

Christopher Plummer, Antibody Selections Team Leader, **GSK**

Colette Johnston, Senior Director, Early Discovery, **Crescendo Biologics**

Dan Bach Kristensen, Principal Scientist, **Symphogen**

Dario Neri, Professor of Chemistry and Applied Biology, **Swiss Federal Institute of Technology Zurich**

David Falck Assistant Professor, **Leiden University Medical Center**

David O'Connell, Associate Professor, School of Biomolecular and Biomedical Science, **University College Dublin**

David Spring, Professor, **University of Cambridge**

Deyarina Gonzalez, Professor of Molecular Medicine, **Swansea University Medical School**

Eliott Harfouche, Managing Partner, **Nodes Advisors**

Elke Prade, Scientist, **Boehringer Ingelheim**

Emmanuel Briand, Associate Director Antibody Discovery, **AgenusBio**

Eric Vivier, CSO, **Innate Pharma**

Erica Lovett, Research Scientist, **AbCellera**

Ezio Bonvini, MD, **MacroGenics, Inc.**

George Badescu, Vice President of Business Development, **Heidelberg Pharma**

Giovanna De Filippi, Business Development Manager EMEA, **Axion Biosystems**

Greg Thurber, Associate Professor in Chemical Engineering and Biomedical Engineering, **University of Michigan**

Gráinne Dunlevy, Head of Protein Sciences, **Abcam**

Gundo Diedrich, Director, Antibody Engineering, **MacroGenics**

Harald Kolmar, Professor, **Technische Universität Darmstadt**

Harbani Malik, Senior Scientist, **Teneobio**

Helena Domingues, Examiner, Joint Cluster Biotechnology, Immunology Directorate, **European Patent Office**

Henry Jin, Director, Business Development, **KBI Biopharma**

Jana Hersch, Ph.D, Scientific Account Manager, **Genedata**

Janice Reichert, Executive Director, **The Antibody Society**

Horst Bierau, Senior Scientific Advisor – Head CMC Science & Intelligence, **Merck**

Jiri Kovarik, Associate Director, **Novartis Institute for BioMedical Research**

James E. Crowe, Director, Vanderbilt Vaccine Center

Professor, Pediatrics and Pathology, Microbiology and Immunology, **Vanderbilt University**

Jannick Bendtsen, CEO, **Pipebio**

Jennifer Jung, Lab Head, Mass Spectrometry, **Sanofi**

Johannes vom Berg, Group Leader, Institute of Laboratory Animal Science, **University of Zurich**
John Delaney, Director, Research Technologies and Collaborations, **Amgen**
John Löfblom, Professor in Combinatorial Protein Engineering, **KTH Royal Institute of Technology**
Jonah Rainey, PhD, VP, Antibody Engineering and Protein Science, **AlivaMab Discovery Services**
Juliette Trepeau, Researcher in Biology, **Pierre Fabre**
Katherine Harris, VP Discovery, **Amgen**
Lamine Mbow, CSO, **Arena Pharmaceuticals**
Lars Stoeckl, Division Manager Service, **Glycotope**
Louise Duffy, SVP & Head of Scientific Project Leaders, **Abzena**
Lauri Peil, Key Account and Technology Officer, **Icosagen**
Linda Klauss, Field Application Specialists, **Gyros Protein Technologies**
Madan Paidhungat, Senior Director Protein Engineering, **CytomX Therapeutics**
Marc Pallardy, Professor and head of the Department of toxicology, **Université Paris-Sud**
Maren Schubert, PostDoc, **TU Braunschweig**
Marc-André Kasper, Head of Research, Chemistry, **Tubulis**
Markus Seeger, Assistant Professor, **University of Zurich**
Mark Samaan, Clinical research Fellow, **Guy's & St Thomas' NHS Foundation Trust**
Marjolein van Egmond, Professor in Oncology and Inflammation, **Amsterdam UMC**
Martin Bertschinger, Deputy Director – Cell Sciences, **Ichnos Sciences**
Matthew Raybould, Postdoctoral Fellow, **University of Oxford**
Methal Albarghouthi, Senior Director, Analytical Sciences, **AstraZeneca**
Minna Mattila, Technology Manager, Immunodiagnostic Reagents Business Unit, **Medix Biochemica Group**
Nanna Luneborg, General Partner, **Forbion**
Néstor Vázquez Bernat, Application Scientist, **Encpicom**
Nicolas Poirier, CSO, **OSE Immunotherapeutics**
Nigel Shipston, Director, Technical Marketing, **FUJIFILM Diosynth Biotechnologies**
Pascal Egloff, Platform Leader, **University of Zurich**
Patrick Bulau, Senior Principal Scientist, **Roche Pharma**
Paul Parren, EVP and Head of R&D, **Lava Therapeutics**
Pawel Stocki, Director of Research, **Ossianix**
Peter Senter, VP, Distinguished Research Fellow, **Seattle Genetics**
Peter Szijj, PhD Student, **UCL**

Philipp Spycher, CEO, **Araris Biotech AG**, PSI Founder Fellow, **PSI Villigen**
Pietro Sormanni, Royal Society University Research Fellow, Department of Chemistry, **University of Cambridge**
Prem Swaroop Mohanty, Life Science Product Specialist and Product Marketing Manager, **Benchling**
Roger Beerli, CSO, **NBE Therapeutics**
Roy Baynes, Senior Vice President and Head Global Clinical Development, Chief Medical Officer, **Merck Sharp and Dohme**
Roza Bidshahri, Senior Research Scientist and BD Liaison, **AbCellera**
Sally Ward, Professor of Molecular Immunology, Director of Translational Immunology, **University of Southampton**
Samuele Cazzamalli, Group Head of Small Molecule Therapeutics, **Philochem**
Sebastian Bunk, Senior Director, Pipeline Research, **Immatics**
Sebastian Schlicker, Director Biologics, **Genedata**
Senior Representative, **Berkeley Lights**
Qingcong Lin, CEO, **Biocytogen**
Senior Representative, **Genscript**
Senior Representative, **Genovac**
Senior Representative, **McSAF Inside Oncology**
Senior Representative, **Sino Biological**
Senior Representative, **Twist Bioscience**
Joska Broekmaat, CTO, **VYCAP**
Shyam Masrini, Principal, **Medicxi**
Soraya Hölper, Project Lead for Portfolio and Strategy, **Sanofi**
Sophia Karagiannis, Professor of Translational Cancer Immunology and Immunotherapy, **Kings College London**
Stefan Zielonka, Associate Director, Protein Engineering and Antibody Technologies, **Merck**
Tanja Ziegengeist, Analytics Expert, **Sanofi**
Thomas Huber, Head of Research, **Almirall**
Thomas Schirrmann, CEO, **Corat Therapeutics**
Timothy Jenkins, Research Fellow, **Technical University of Denmark**
Thoms Pillow, Senior Scientist, **Genentech**
Tony Polverino, CSO, **Zymeworks**
Tracey Mullen, CEO, **Abveris Antibody**
Udo Roth, Laboratory Head MS, **Sanofi**
Victor Greiff, Associate Professor, Department of Immunology, **University of Oslo**
Victor Le, PostDoc in Protein Characterization, **Novartis**
Yariv Wine, Senior Lecturer (Assistant Professor), **Tel Aviv University**

Day 1 – Tuesday 9th November

8:00am	Registration opens			
	Opening Keynotes – ROOM MONTREAL			
9:00am	Welcome from Terrapinn			
9:05am	Chair’s opening remarks Alain Beck , Senior Director, Biologics CMC and Developability, Pierre Fabre , Associate Editor, <i>mAbs</i> (CONFIRMED)			
9:10am	Antibody-Drug Conjugates for Cancer Therapy Peter Senter , VP, Distinguished Research Fellow, Seattle Genetics (CONFIRMED)			
9:35am	Evolving Manufacturing Strategies for Monoclonal Antibody Therapeutics Nigel Shipston , Director, Technical Marketing, FUJIFILM Diosynth Biotechnologies (CONFIRMED)			
10:00am	Sponsored keynote panel discussion: Next generation antibody therapeutics: discovery, development and beyond Chair: Mio Muelthaler , Executive Account Manager, Berkeley Lights (CONFIRMED) Paul Parren , EVP and Head of R&D, Lava Therapeutics (CONFIRMED) Arne Skerra , Professor, Biological Chemistry, TU Munich & XL-protein (CONFIRMED) Mahendra Deonarain , CEO & CSO, Antikor Biopharma (CONFIRMED) Peter Senter , VP, Distinguished Research Fellow, Seattle Genetics (CONFIRMED)			
10:40am	Networking Break			
11:30am	Round Table Sessions – ROOM SINGAPORE <i>There will be one rotation, each 30 minutes with 5 minutes to change over</i>			
	<p align="center">TABLE 1</p> <p align="center">Analytical and structural characterization of mAbs, biosimilars, ADCs, BsAbs, and Fc fusion proteins</p> <p>Alain Beck, Senior Director, Biologics CMC and Developability, Pierre Fabre, Associate Editor, <i>mAbs</i> (CONFIRMED)</p>	<p align="center">TABLE 2</p> <p align="center">Developability of multispecifics</p> <p align="center">OPEN ROUNDTABLE - DELEGATES ARE ENCOURAGED TO DISCUSS AMONG THEMSELVES ON THE TOPIC ABOVE</p>	<p align="center">TABLE 3</p> <p align="center">Next Generation Antibody Discovery Platforms - Challenges and Opportunities</p> <p align="center">Roza Bidshahri, Senior Research Scientist and BD Liaison, AbCellera(CONFIRMED)</p>	<p align="center">TABLE 4</p> <p align="center">Applying AI and machine learning to Protein Design</p> <p align="center">Nicolás Lopez Carranza, Deepchain Product Lead, InstaDeep (CONFIRMED)</p>
	<p align="center">TABLE 5</p> <p align="center">Antibody Manufacturing - How does the Future Look?</p> <p align="center">Nigel Shipston, Director, Technical Marketing, FUJIFILM Diosynth Biotechnologies</p>	<p align="center">TABLE 6</p> <p align="center">Tracking Social Determinants of Health During the COVID-19 Pandemic. Why Partnering With Healthcare Organizations Overcomes Barriers In Healthcare</p>	<p align="center">TABLE 7</p> <p align="center">Advancing ADCs – Novel Payloads</p> <p align="center">George Badescu, Vice President of Business Development, Heidelberg Pharma (CONFIRMED)</p>	<p align="center">TABLE 8</p> <p align="center">Investing in biologics</p> <p align="center">Shyam Masrini, Principal, Medicxi (CONFIRMED)</p>

		<p>Mario J. Paredes, Chief Executive Officer, SOMOS Community Care Henry Chen, President, SOMOS Community Care Yomaris Pena, Director of Emergency Response, SOMOS Community Care</p>			
12:35pm	Networking Lunch				
	Protein Engineering ROOM SINGAPORE	Bispecifics & Multispecifics ROOM SYDNEY	Infectious Diseases ROOM OSAKA	Manufacture & Bioprocessing ROOM SAMARKAND	Technology Showcase <i>Reserved for supporting partners</i> ROOM RIO
	Chair: Arne Skerra , Professor, Biological Chemistry, TU Munich & XL-protein (CONFIRMED)	Chair: Thomas Huber , Head of Research, Almirall (CONFIRMED)	Chair: Matthew Raybould , Postdoctoral Fellow, University of Oxford (CONFIRMED)	Chair: Nigel Shipston , Director, Technical Marketing, FUJIFILM Diosynth Biotechnologies	Chair:
2:00pm	<p>Novel 10 kDa scaffold libraries for selection of peptide inhibitors - case studies in GPCR and amyloid therapeutic development with phage display</p> <p>David O'Connell, Associate Professor, School of Biomolecular and Biomedical Science, University College Dublin (CONFIRMED)</p>	<p>Bispecific gamma-delta T cell engagers</p> <p>Paul Parren, EVP and Head of R&D, Lava Therapeutics (CONFIRMED)</p>	<p>Discovery of broadly neutralizing recombinant antibodies as next-generation antivenoms.</p> <p>Anne Ljungars, Senior Scientist, Technical University of Denmark (CONFIRMED)</p>	<p>Cell line development for innovative antibody formats at Ichnos Sciences</p> <p>Martin Bertschinger, Deputy Director – Cell Sciences, Ichnos Sciences (CONFIRMED)</p>	<p>Clone and process optimization – Combining productivity with quality goals</p> <p>Lars Stoeckl, Division Manager Service, FyoniBio (CONFIRMED)</p>
2:20pm	<p>Twist Biopharma: Writing the Future of Biologics to Discover and Optimize Single Domain Antibodies</p> <p>Aaron Sato, CSO, Twist Bioscience (CONFIRMED)</p>	<p>Expanding the therapeutic window of CD3-engaging DART® and TRIDENT™ molecules</p> <p>Gundo Diedrich, Director, Antibody Engineering, MacroGenics (CONFIRMED)</p>	<p>Development and novel administration approaches of SARS-CoV-2 neutralizing antibodies</p> <p>Mart Ustav Jr., CSO, Icosagen (CONFIRMED)</p>	<p>Accelerating bioprocess workflows with microfluidic, immunoassay-based parallel impurity analysis</p> <p>Linda Klauss, Field Application Specialists, Gyros Protein Technologies (CONFIRMED)</p>	<p>Finding the Best Cells by Using Light to Manipulate Single Cells on a Nanofluidic Chip</p> <p>Mio Muelthaler, Executive Account Manager, Berkeley Lights (CONFIRMED))</p>
2:40pm	<p>One-Stop Customized Service for Recombinant Protein Expression and Antibody Development</p>	<p>An Integrated Development Approach to Bispecifics: A Portfolio Review</p>	<p>Development of glyco-humanized neutralizing polyclonal antibodies against</p>	<p>A Global Intercompany Precision and Robustness Validation of icIEF methodology for the Analysis</p>	<p>The Puncher platform - Antibody discovery and Cell line generation</p>

	Linlin Zhang , Technical Specialist, Sino Biological (CONFIRMED)	Henry Jin , Director, Business Development, KBI Biopharma	Bernard Vanhove , CSO, Xenothera (CONFIRMED)	of NIST-mAb and a Fusion Protein Minna Mattila , Technology Manager, Immunodiagnostic Reagents Business Unit, Medix Biochemica Group (CONFIRMED)	Joska Broekmaat , CTO, VYCAP (CONFIRMED)
3:00pm	Antibodies with on/off switches: Engineering strategies for fine-tuning of antibody activity Harald Kolmar , Professor, Technische Universität Darmstadt (CONFIRMED)	Addressing unmet patient needs in immune-inflammatory diseases through monoclonal / bispecific antibodies Thomas Huber , Head of Research, Almirall (CONFIRMED)	Human B cell responses to emerging infections James E. Crowe , Director Vanderbilt Vaccine Center Professor, Pediatrics and Pathology, Microbiology and Immunology, Vanderbilt University (CONFIRMED)	Multi-quadrupole-ICP-MS Analysis of the Elemental Composition in Cell Culture Media Michael Petrich , Subject Matter Expert Atomic Spectroscopy EMEAI, Perkin Elmer (CONFIRMED)	Bioinformatics made simple! Jannick Bendtsen , CEO, Pipebio (CONFIRMED)
3:20pm	COR-101 – Development of a COVID-19 specific antibody to treat hospitalized patients Andreas Herrmann , CEO, Corat Therapeutics (CONFIRMED)	High throughput formulatability and pH screening for complex biologics Ahmed Besheer , Head formulation development, Lonza (CONFIRMED)	Tackling the evolving SARS-CoV-2 with antibodies Marit van Gils , Associate Professor, University of Amsterdam (CONFIRMED)	Cysteine in cell culture media induces acidic IgG1 species by disrupting the disulfide bond network Elke Prade , Scientist, Boehringer Ingelheim (CONFIRMED)	Accelerating Immunotherapy Drug Development Targeting Checkpoints with Robust MOA-Based Assays Alexander Baumann , Head of European Business Development, DiscoverX Products , Eurofins DiscoverX products (CONFIRMED)
3:40pm	Networking Break				
	Protein Engineering ROOM SINGAPORE	Bispecifics & Multispecifics ROOM SYDNEY	Infectious Diseases ROOM OSAKA	Immunogenicity ROOM SAMARKAND	Technology Showcase ROOM RIO
	Chair: Horst Bierau , Senior Scientific Advisor – Head CMC Science & Intelligence, Merck	Chair: Paul Parren , EVP and Head of R&D, Lava Therapeutics (CONFIRMED)	Chair: Anne Ljungars , Senior Scientist, Technical University of Denmark (CONFIRMED)	Chair:	Chair:
4:30pm	Blood-Brain Barrier Delivery in Non-Human Primates by Single Domain VNAR Antibodies to TfR1	A bispecific antibody agonist of the IL-2 heterodimeric receptor promotes in vivo expansion of CD8 and NK cells	Human monoclonal antibodies as therapeutics against SARS-COV-2 and related viruses	Immunogenicity and Immunotoxicity of biologics Marc Pallardy , Professor and head of the Department of	A Breakthrough Cell Count and Viability label-free method for High-Throughput Cell Culture Monitoring in bioreactors

	Pawel Stocki , Director of Research, Ossianix (CONFIRMED)	Katherine Harris , VP Discovery, Amgen (CONFIRMED)	Dimiter Dmitrov , Director, Center for Antibody Therapeutics, University of Pittsburgh (CONFIRMED)	toxicology, Université Paris-Saclay (CONFIRMED)	Geoffrey Esteban , CEO, IPRASENSE (CONFIRMED)
4:50pm	Discovery of a potent human antibody that neutralizes SARS-CoV-2 and its variants Erica Lovett , Research Scientist, AbCellera (CONFIRMED)	IgG-like bispecific antibody design and discovery for multiple immuno-oncology target pairs Chris Plummer , Antibodies Selection Team Leader, GSK (CONFIRMED)	Covid-19: Lessons from the Front – And an Invitation to Join Us There Ramon Tallaj , Founder and Chairman, SOMOS Community Care (CONFIRMED)	Non-clinical immunogenicity assessment : an update of the T cell response specific for therapeutic antibodies Bernard Maillere , Head of laboratory, CEA, Head, Immunology and Biotherapies, Université Paris-Sud (CONFIRMED)	Developing Immunotherapies with Axion BioSystems Maestro Z Platform for Impedance-Based Cellular Assays Giovanna De Filippi , Business Development Manager EMEA, Axion Biosystems (CONFIRMED)
5:10pm	Affibody molecules as aggregation inhibitors for neurodegenerative disorders John Löfblom , Professor in Combinatorial Protein Engineering, KTH Royal Institute of Technology (CONFIRMED)	Next-Generation In Vivo Models To Streamline Discovery of Antibody Therapeutics Qingcong Lin , CEO, Biocytogen (CONFIRMED)	Epitope profiling of coronavirus-binding antibodies using computational structural modelling Matthew Raybould , Postdoctoral Fellow, University of Oxford (CONFIRMED)	A Practical Approach to Mitigating Immunogenicity Concerns in Novel Biotherapeutics Samuel Pine , Head of Bioanalysis and Immunogenicity, Ablynx/Sanofi (CONFIRMED)	Evaluating the Stability of Bispecific Antibodies using High Throughput Platforms Pauline Scholler , Life science research reagents & readers specialist, PerkinElmer (CONFIRMED)
5:30pm	Bispecific CARs using Crescendo VH Colette Johnston , Senior Director, Early Discovery, Crescendo Biologics (CONFIRMED)	Multispecific MATCH antibodies – novel therapeutics with tumor targeted immunomodulatory functions and beneficial safety profile Tea Gunde , Vice President Discovery, Numab (CONFIRMED)	COR-101 – fast track development of a SARS-CoV-2 neutralizing antibody drug Thomas Schirrmann , CEO, Corat Therapeutics (CONFIRMED)	Enabling discovery of broadly-neutralising antibodies: Venom toxin clustering and unravelling snake venom complexity Timothy Jenkins , Research Fellow, Technical University of Denmark (CONFIRMED)	Upscaling strategies for a mAb process Peter Eiermann , Team Manager - Biopurification Specialist, Pall Corporation (CONFIRMED)
5:50pm	Robust, modular approaches to binder valency engineering and receptor agonism Thomas fryer , Industrial Postdoc, Technical University of Denmark (CONFIRMED)	Targeting of tumor-specific peptide antigens with bispecific T Cell-Engaging Receptor (TCER®) molecules Sebastian Bunk , Senior Director, Pipeline Research, Immatics (CONFIRMED)	Targeting conserved outer membrane proteins of gram-negative pathogens with sybodies Markus Seeger , Assistant Professor, University of Zurich (CONFIRMED)	Immunogenicity risk assessment Vibha Jawa , Executive Director, BMS (CONFIRMED)	
6:10pm	Offsite Networking Drinks				

Day 2 – Wednesday 10th November

Keynotes: Antibodies & Immunotherapy Joint Plenary

ROOM MONTREAL

9:00am	Chair's opening remarks Lamine Mbow, CSO, Arena Pharmaceuticals (CONFIRMED)				
9:05am	Novel approaches for antibody cancer immunotherapy Christian Klein, Head of Oncology Programmes, Department Head Cancer Immunotherapy, Roche Innovation Center Zurich, Roche Pharma Research and Early Development (CONFIRMED)				
9:30am	Accelerating Novel Immunotherapeutic Modality Discovery through Digitalization Sebastian Schlicker, Head, Operations - Biologics, Genedata (CONFIRMED)				
9:55am	PD-1 antibodies either as precision medicine informed monotherapy or combinations are transforming cancer care Roy Baynes, Senior Vice President and Head Global Clinical Development, Chief Medical Officer, Merck Sharp and Dohme (CONFIRMED)				
10:20am	Accelerating Biopharma R&D: Merging Automation & Data Management to Enable Collaboration and Innovation Moderator: Jana Hersch, Ph.D, Scientific Account Manager, Genedata Ezio Bonvini, CSO, Macrogenics Soraya Höpfer, Project Lead for Portfolio and Strategy, Sanofi Uwe Wittenberg, Director Research Informatics, Merck Alexander Jung, Head of Digitalization Biologicals Development CMC, Boehringer Ingelheim Markus Enzelberger, Partner, Versant Ventures Björn Hüber, Team Leader Data Management, Novartis				
11:00am	Networking Break				
	Protein Engineering ROOM MONTREAL	Bispecifics & Multispecifics ROOM SINGAPORE	Armed Antibodies ROOM SYDNEY	CMC & Developability ROOM OSAKA	
	Chair: Anne Ljungars, Senior Scientist, Technical University of Denmark (CONFIRMED)	Chair: Katherine Harris, VP Discovery, Amgen (CONFIRMED)	Chair: Mahendra Deonarain, CEO & CSO, Antikor Biopharma (CONFIRMED)	Chair: Alain Beck, Senior Director, Biologics CMC and Developability, Pierre Fabre, Associate Editor, mAbs (CONFIRMED)	
11:40am	Novel Solution For High Throughput Antibody And Protein Purification Using Magnetic Beads	Efficient NK cell redirection by targeting natural cytotoxicity receptor NKp30 Stefan Zielonka, Associate Director, Protein Engineering	TubTecans: P5-labelling for technology-enabled payload solutions targeting topoisomerase-I	State of the art characterization of antibody based products Alain Beck, Senior Director, Biologics CMC and	

	Nishant Saxena , Product Manager, Protein Purification, Genscript (CONFIRMED)	and Antibody Technologies, Merck (CONFIRMED)	Marc-André Kasper , Head of Research, Chemistry, Tubulis (CONFIRMED)	Developability, Pierre Fabre , Associate Editor, mAbs (CONFIRMED)	
12:00pm	Development of new protease-sensitive masked antibodies Benjami Oller-Salvia , Assistant Professor, IQS School of Engineering, Ramon Llull University (CONFIRMED)	Cell-antibody binding kinetics analyzed with an automated biosensor Ulrich Rant , CEO, Dynamic Biosensors	A novel IL12-based immunocytokine targeting Fibroblast Activation Protein (FAP) for the treatment of cancer Lisa Nidal , Industrial PhD student, Philochem (CONFIRMED)	Beyond Antibodies – Developing Robust CMC Approaches for Next Generation Modalities Louise Duffy , SVP & Head of Scientific Project Leaders, Abzena (CONFIRMED)	
12:20pm	Accelerating Antibody Engineering with Modern Informatics Gaurav Agrawal , Business Value Manager, Benchling (CONFIRMED)	intein-mediated high throughput screening of bispecific antibodies Achim Doerner , Principal Researcher, Merck Healthcare KGaA, Darmstadt (CONFIRMED)	ADCITMER® , an ADC for neuroendocrine carcinoma Audrey Desgranges , Chief Operating Officer, McSAF Inside Oncology (CONFIRMED)	Current views on N-glycolyl-neuraminic acid in biotherapeutics Horst Bierau , Senior Scientific Advisor – Head CMC Science & Intelligence, Merck (CONFIRMED)	
12:40pm	AI and Protein Design: new opportunities Nicolás Lopez Carranza , Deepchain Product Lead, InstaDeep (CONFIRMED)	Title TBA Pascal Egloff , Platform Leader, University of Zurich (CONFIRMED)		Assessment of size variants for antibody co-formulations Patrick Bulau , Senior Principal Scientist, Analytical Development & Quality Control, Roche Pharma (CONFIRMED)	
1:00pm	Networking Lunch				
	Antibodies for Immunotherapy <i>Shared track with the Immunotherapy Congress</i> ROOM MONTREAL	mAbs ROOM SINGAPORE	Armed Antibodies ROOM SYDNEY	CMC & Developability ROOM OSAKA	Biosimilars Emerging Regions Virtual Session ROOM SAMARKAND
	Chair: Thomas Schirrmann , CEO, Corat Therapeutics (CONFIRMED)	Chair: Jiri Kovarik , Associate Director, Novartis Institute for BioMedical Research (CONFIRMED)	Chair: Marc-André Kasper , Head of Research, Chemistry, Tubulis (CONFIRMED)	Chair: Alain Beck , Senior Director, Biologics CMC and Developability, Pierre Fabre , Associate Editor, mAbs (CONFIRMED)	

2:20pm	Bispecific anti-PD1/IL7 preclinical evaluation Nicolas Poirier , Chief Scientific Officer, OSE ImmunoTherapeutics (CONFIRMED)	Structural lessons from antibodies developed against disordered peptide antigens as tools for the clinical application of PASylation technology Arne Skerra , Professor, Biological Chemistry, TU Munich & XL-protein (CONFIRMED)	Linker matters: highly stable and efficient ADCs made with native antibodies and peptide linkers Philipp Spycher , CEO, Araris Biotech AG , PSI Founder Fellow, PSI Villigen (CONFIRMED)	Empowering LC-MS characterization of therapeutic proteins in early phase development Victor Le , PostDoc in Protein Characterization, Novartis (CONFIRMED)	Biosimilar breakthrough: China to Global Ping Cao , VP of Business Development, Shanghai Henlius (Confirmed)
2:40pm	B cells and antibodies in patients with solid tumours Sophia Karagiannis , Professor of Translational Cancer Immunology and Immunotherapy, Kings College London (CONFIRMED)	Leading Strategies for Antibody Discovery Against GPCRs – Genetic Immunization and Berkeley Lights Beacon® Amelie Kutschera , Single B Cell Scientist, Genovac (CONFIRMED)	Pan-tumoral Small Molecule-Drug Conjugates targeting Fibroblast Activation Protein in solid lesions Samuele Cazzamalli , Group Head of Small Molecule Therapeutics, Philochem (CONFIRMED)	Multi-Attribute Monitoring (MAM)™ for process development of Nanobody and Synthorin drug candidates Udo Roth , Laboratory Head MS, Sanofi (CONFIRMED)	Title: TBA Bert E. Thomas , Senior Vice President, Business Development, Bio-Thera Pharmaceuticals (Confirmed)
3:00pm	A Platform Approach for Generation of BiSpecific Antibodies for Immunotherapy Jonah Rainey , PhD, VP, Antibody Engineering and Protein Science, AlivaMab Discovery Services (CONFIRMED)	Impact of human and non-human N-linked glycans on in vivo clearance of monoclonal antibody Methal Albarghouthi , Senior Director, Analytical Sciences, AstraZeneca (CONFIRMED)	ATACs: a Unique New Mode of Action to Fight Cancer George Badescu , Vice President of Business Development, Heidelberg Pharma (CONFIRMED)	A Symphony of Separation Techniques Hyphenated to MS for In-Depth Characterization - Applications and Case Studies from a Biopharmaceutical Development Lab Dan Bach Kristensen , Principal Scientist, Symphogen (CONFIRMED)	Biosimilars in Brazil Tiago Rocca , Strategic Partnerships and Business Development Manager, Instituto Butantan, Government of Brazil (Confirmed)
3:20pm	A tumour activated IL-15 immunocytokine Juliette Trepreau , Researcher in Biology, Pierre Fabre (CONFIRMED)	Trends in Antibody Discovery and Development Libby Naylor , Advanced Therapies UK Account Manager, Genscript (CONFIRMED)	Development of Antibody Fragment Drug Conjugates (FDCs), tailored for Solid Tumours Mahendra Deonarain , CEO & CSO, Antikor Biopharma (CONFIRMED)		
3:40pm	Harnessing innate immunity in cancer therapy	Artificial intelligence methods to detect dengue-specific	Avoiding ADC Misdirection: Designing clinically effective		

	Eric Vivier, CSO, Innate Pharma (CONFIRMED)	antibody repertoire and sequence patterns Enkelejda Miho, Head of Master of Scient in Medical Informatics, FHNW University of Applied Sciences and Arts Northwestern Switzerland (CONFIRMED)	agents from in vitro, in vivo, and in silico data Greg Thurber, Associate Professor in Chemical Engineering and Biomedical Engineering, University of Michigan (CONFIRMED)		
4:00pm	Networking Break				
	Antibodies for Immunotherapy <i>Shared track with the Immunotherapy Congress</i> ROOM MONTREAL	MAbs ROOM SINGAPORE	Armed Antibodies ROOM SYDNEY	Proteomics & Mass Spectrometry ROOM OSAKA	Research Hub ROOM SAMARKAND
	Chair: Thomas Schirrmann, CEO, Corat Therapeutics (CONFIRMED)	Chair: Jiri Kovarik, Associate Director, Novartis Institute for BioMedical Research (CONFIRMED)	Chair: Benjami Oller-Salvia, Assistant Professor, IQS School of Engineering, Ramon Llull University (CONFIRMED)	Chair: David Falck Assistant Professor, Leiden University Medical Center (CONFIRMED)	Chair: Peter Szijj, PhD Student, UCL (CONFIRMED)
4:40pm	VHH as building blocks for immune and tumour cell-targeting Bill Eldridge, CSO, Isogenica (CONFIRMED)	The Biologic Revolution in Inflammatory Bowel Disease: Hits, Misses and What Comes Next Mark Samaan, Consultant Gastroenterologist, Guy's & St Thomas' NHS Foundation Trust (CONFIRMED)	ADC Advances David Spring, Professor, University of Cambridge (CONFIRMED)	Keeping pace with the increasing complexity of Multispecific Biotherapeutics: Bioanalysis of Mispairing & In-depth Peptide Mapping Analysis Soraya Hölper, Project Lead for Portfolio and Strategy, Sanofi (CONFIRMED)	Lightning Fast Bispecifics - Rapid generation of modular bispecific antibodies with pyridazinediones Peter Szijj, PhD Student, UCL (CONFIRMED)
5:00pm	Exclusively local IL-12 immunotherapy of brain cancer with a compartment locked fusion cytokine Johannes vom Berg, Group Leader, Institute of Laboratory Animal Science, University of Zurich (CONFIRMED)	How innovations in antigen development for RabMab discovery has led to delivery of high quality recombinant protein reagents that can be used from research through to the clinic Gráinne Dunlevy, Head of Protein Sciences, Abcam (CONFIRMED)	Targeting the Receptor for Advanced Glycation Endproducts (RAGE): An ADC Perspective. Deyarina Gonzalez, Professor of Molecular Medicine, Swansea University Medical School (CONFIRMED)	Glycoform-resolved pharmacokinetic studies by combining glycoengineering and bottom-up glycoprotein analysis David Falck Assistant Professor, Leiden University Medical Center (CONFIRMED)	Baculovirus-free Insect Cell Expression System for expression of antibodies, antigens and VLPs Maren Schubert, PostDoc, TU Braunschweig (CONFIRMED)

5:20pm	<p>A Novel Bispecific Antibody Platform that Elicits Efficient Tumor Lysis with Minimal Cytokine Release in Liquid and Solid Tumors</p> <p>Harbani Malik, Senior Scientist, Teneobio (CONFIRMED)</p>	<p>Optimal use of mAbs (biotherapeutics); from pregnancy, via babies to long-term treatment</p> <p>Annick de Vries, PhD. Director Pharma & Biotech Services, Sanquin Health Solutions, Sanquin (CONFIRMED)</p>	<p>Optimizing DNA Damaging Payload ADCs</p> <p>Thomas Pillow, Senior Scientist, Genentech (CONFIRMED)</p>	<p>High Throughput and Format-agnostic Mispairing Assay for Multispecific Antibodies using Intact Mass Spectrometry</p> <p>Jennifer Jung, Lab Head, Mass Spectrometry, Sanofi (CONFIRMED)</p>	<p>Targeting proteins with biologicals inside cells</p> <p>Andrea Marschall, Post-Doc, Brandeis University (CONFIRMED)</p>
5:40pm	<p>Bispecific $\gamma\delta$-T cell engagers for cancer immunotherapy</p> <p>Hans van der Vliet, CSO, Lava Therapeutics (CONFIRMED)</p>	<p>The landscape of high-affinity human antibodies against intratumoral antigens</p> <p>Daniele Biasci, VP of Immunology, Absci</p>	<p>SMAC™-Technology: a highly efficient method for the generation of homogeneous, site-specifically conjugated antibody drug conjugates</p> <p>Roger Beerli, CSO, NBE Therapeutics (CONFIRMED)</p>		<p>Antivenom unchained – engineering antibody affinity and cross-reactivity by chain-shuffling</p> <p>Line Ledsgaard, PhD Student, Technical University of Denmark (CONFIRMED)</p>
6:00pm	Onsite Networking Drinks				

Day 3 – Thursday 11th November

Academic Keynotes

ROOM SINGAPORE

9:00am	Chair's opening remarks Ahuva Nissim , Professor, William Harvey Research Institute, Queen Mary University (CONFIRMED)			
9:05am	The SHREAD platform: SHielded, REtargeted ADenovirus for the paracrine delivery of therapeutics Andreas Plueckthun , Professor of Biochemistry, Director, Department of Biochemistry, University of Zurich (CONFIRMED)			
9:30am	Antibody-cytokine fusions: from discovery to Phase III clinical trials Dario Neri , Professor of Chemistry and Applied Biology, Swiss Federal Institute of Technology Zurich (CONFIRMED)			
9:55am	Targeting FcRn for the generation of therapeutics Sally Ward , Professor of Molecular Immunology, Director of Translational Immunology, University of Southampton (CONFIRMED)			
10:20am	Networking Break			
	Antibodies for Immunotherapy <i>Shared track with the Immunotherapy Congress</i> ROOM SINGAPORE	Analytics, Screening & Immune Repertoire Technologies ROOM RIO	Computational Approaches ROOM OSAKA	Nanobodies, Peptides & Non-antibody Formats ROOM SAMARKAND
	Chair: Samuele Cazzamalli , Group Head of Small Molecule Therapeutics, Philochem (CONFIRMED)	Chair: Christoph Merten , Professor, Swiss Federal Institute of Technology Lausanne (EPFL) (CONFIRMED)	Chair: Pietro Sormanni , Royal Society University Research Fellow, Department of Chemistry, University of Cambridge	Chair: Marit van Gils , Associate Professor, University of Amsterdam (CONFIRMED)
11:10am	Complete genetic quality control for antibody, viral vector and ATMP manufacturing with TLA Martijn Kelder , Sales Director, Cergentis (RESERVED)	Functional screening of B- and T-cell repertoires in a droplet microfluidic format Christoph Merten , Professor, Laboratory for Biomedical Microfluidics, Swiss Federal Institute of Technology Lausanne (EPFL) (CONFIRMED)	De novo design of binding nanobodies Pietro Sormanni , Royal Society University Research Fellow, Department of Chemistry, University of Cambridge (CONFIRMED)	Exploiting the unique epitope targeting ability of soloMERS to develop new therapeutic biologics Caroline Barelle , CEO & Co-Founder, Elasmogen (CONFIRMED)
11:30am	New tricks for old targets: Fc-enhanced CTLA-4 and TIGIT mAbs promote optimal T cell activation and improved anti-tumor immunity.	Title TBA Yariv Wine , Senior Lecturer (Assistant Professor), Tel Aviv University (CONFIRMED)	NGS-powered antibody discovery: Implementing robust and scalable candidate selection Néstor Vázquez Bernat , Application Scientist, Enpicom (CONFIRMED)	Title TBA Iwan Zimmermann , Co-Founder & CSO, Linsker Therapeutics (CONFIRMED)

	Emmanuel Briend , Associate Director Antibody Discovery, Agenus Bio (CONFIRMED)			
11:50am	Bispecific DART Molecules: From Bench to the Bedside” Ezio Bonvini , MD, MacroGenics, Inc. (CONFIRMED)	Lessons Learned from 2+ Years of Discovering Functional Antibodies on the Beacon Colby Souders , CSO, Abveris Antibody (CONFIRMED)	Benchmarking machine-learning-based prediction and generation of antibody specificity Victor Greiff , Associate Professor, Department of Immunology, University of Oslo (CONFIRMED)	Structure guided design of peptides for VHH half-life extension Carlo Boutton , Global Head Innovation, Large Molecule Research Platform, Sanofi (CONFIRMED)
12:10pm	Title TBA Marjolein van Egmond , Professor in Oncology and Inflammation, Amsterdam UMC (CONFIRMED)	Humanization of antibodies using a machine learning approach on large-scale repertoire data Alissa Hummer , PhD Student, University of Oxford (CONFIRMED)	Panel discussion: computational approaches for antibody discovery & development Chair: Elliott Harfouche , Managing Partner, Nodes Advisors (CONFIRMED)	
12:30pm		Secretion-based live cell sorting using droplet microfluidic; application to hybridomas selection Alain Wagner , Research Director and Head, BioFunctional Chemistry Lab (CONFIRMED)	Pietro Sormanni , Royal Society University Research Fellow, Department of Chemistry, University of Cambridge (CONFIRMED) Marcin J. Skwark , Bioinformatics Lead, InstaDeep (CONFIRMED)	
12:50pm	Networking Lunch			
	Combined Festival of Biologics plenary session ROOM SINGAPORE			
	Chair: Jacqueline Delmont , Chief Medical Officer, SOMOS			
2:00pm	Antibodies to watch in 2022 Janice Reichert , Executive Director, The Antibody Society (CONFIRMED)			
2:20pm	Biosimilars: from science to market dynamics Fernando de Mora , Professor of Pharmacology, Universidad Automatica Barcelona (Confirmed)			

2:40pm	Keynote panel discussion: Exploring clinical needs and novel indications Chair: Anders Pedersen , Medical Lead in Global Clinical Development, Almirall (CONFIRMED) Thomas Hach , Executive Director, Patient Engagement Cardiovascular, Renal & Metabolism, Novartis (CONFIRMED) Dario Neri , Professor of Chemistry and Applied Biology, Swiss Federal Institute of Technology Zurich (CONFIRMED)
3:20pm	End of Conference – see you next year!

FESTIVAL OF BIOLOGICS



World Immunotherapy Congress

Basel Congress Center

9th-11th November 2021

Advisory Board:

Ahuva Nissim, Professor in Antibody and Therapeutic Engineering Biochemical Pharmacology, William Harvey Research Institute, **Queen Mary University**

Alain Beck, Senior Director, Biologics CMC and Developability, **Pierre Fabre**, Associate Editor, *mAbs*

Christian Klein, Head of Oncology Programmes, Department Head Cancer Immunotherapy, **Roche Innovation Center Zurich**, **Roche Pharma Research and Early Development**

Roy Baynes, SVP, Head Global Clinical Development, **MSD**

Alexander Eggermont, Chief Scientific Officer, **Princess Máxima Center for Pediatric Oncology**

Farshad Guirakhoo, Chief Scientific Officer, **Vaxxinity**

Joseph Eid, Senior Vice President and Head, Global Medical Affairs, **BMS**

Confirmed speakers

Ahuva Nissim, Professor, **William Harvey Research Institute, Queen Mary University**
Alain Vertes, Managing Director, **NxR Biotechnologies**
Alfonso Quintas, Chief Medical Officer, **TCR2 Therapeutics**
Ali Mohamed, Vice President CMC, **Immatics**
Amrik Basran, Chief Scientific Officer, **Avacta**
Anders Pedersen, Medical Lead in Global Clinical Development, **Almirall**
Andrew Goodearl, Senior Director, **Abbvie Bioresearch Center**
Andy Lewin, Vice President, Business Development, Manufacturing, **Oxford Biomedica**
Angelica Loskog, CEO, **LOKON Pharma**
Brent Rice, Chief Commercial Officer, **Autolus**
Brian Champion, CSO, **PsiOxus Therapeutics**
Bruno Gomes, Global Head of Biomarkers Oncology, **Roche**
Christian Klein, Head of Oncology Programmes, Department Head Cancer Immunotherapy, **Roche Innovation Center Zurich, Roche Pharma Research and Early Development**
Christophe Le Tourneau, Head, Department of Drug Development & Innovation, **Institut Curie**
Christophe Queva, CSO, **Oncorus**
Daniel Bright, Senior Global Project Manager, **Ferring Pharmaceuticals**
Daniel Muthas, Head of Data Science and Bioinformatics, **Astrazeneca**
Dario Neri, CEO & CSO, **Philogen**
David DiLillo, Associate Director, **Regeneron**
David Pyrcce, CEO, **Devacell**
Dr Michele Zagnoni, Reader, **University of Strathclyde**
Ed Schuurin, Professor of Molecular Oncological Pathology, Clinical Scientist in Molecular Pathology, **University Medical Center Groningen (UMCG)**
Eleni Chantzoura, Team Leader – Immune Receptor Discovery, **AgenTus Therapeutics**
Eric Halioua, President & CEO, **PDC*line Pharma**
Eric Vivier, CSO, **Innate Pharma**
Erik Manting, CEO, **Immunicum**
Emmanuel Briend, Associate Director Antibody Discovery, **Agenus Bio**
Ezio Bonvini, MD, **MacroGenics, Inc.**
Farshad Guirakhoo, Chief Scientific Officer, **Vaxxinity**
Federica Frascetti, Associate Director, engineering, Large Molecule External Manufacturing, Technical Operations, **Merck**
Geoffrey Lynn, CEO & Co-Founder, **Avidea Technologies**

Gregor Hutter, Research Group Leader, **University of Basel**
Hans S. Keirstead, Chief Executive Officer, **AIVITA Biomedical, Inc.**
Hans van der Vliet, CSO, **Lava Therapeutics**
Hanspeter Gerber, CEO and CSO, **3T Biosciences**
Harbani Malik, Senior Scientist, **Tenebio**
Heinz Laubli, Senior Physician, Medical Oncology, **University Hospital Basel**
Heinz Lubenau, Chief Executive Officer, **Vaxxim**
Igor Bilinsky, Chief Operating Officer, **Iovance Biotherapeutics**
Ingrid Teige, VP of Preclinical Research, **BiolInvent**
Ignacio Núñez, Executive Director, Manufacturing, **University of Pennsylvania**
Jean-Cosme Dodart, SVP, Preclinical R&D, **United Neuroscience**
Jeanette Leusen, Associate Professor, Laboratory, Translational Immunology, **UMC Utrecht**
Jennifer Bolsee, Research & Development Senior Scientist, **Celyad Oncology**
Jessica Flechtner, Chief Scientific Officer, **Genocea Biosciences**
Jing Zhao, Chief Medical Officer, **Refuge Biotech**
Johannes vom Berg, Group Leader, Institute of Laboratory Animal Science, **University of Zurich**
Jonah Rainey, PhD, VP, Antibody Engineering and Protein Science, **AlivaMab Discovery Services**
Juliette Trepeau, Researcher in Biology, **Pierre Fabre**
Kate Broderick, Senior Vice President and R&D, **Inovio Pharmaceuticals**
Klaus Lindpaintner, Chief Scientific Officer and Chief Marketing Officer, **InterVenn**
Lakshmikanth Gandikota, Vice President, Innovation Science and Technology, Biologics and Cell & Gene Therapy **Intas Pharmaceuticals**
Lamine Mbow, CSO, **Arena Pharmaceuticals**
Leonardo Borrás, CSO, **CDR-Life**
Limin Shang, Director of Pharmacology, **Light Chain Bioscience – A Brand of Novimmune SA**
Lindy Durrant, Professor of Cancer Immunotherapy, **University of Nottingham**
Maggie Cheang, Team Leader, Genomic Analysis – Clinical Trials, **Institute of Cancer Research**
Maria Fiammetta Romano, Associate Professor of Biochemistry, **University of Naples “Federico II”**
Marjolein van Egmond, Professor in Oncology and Inflammation, **Amsterdam UMC**
Markus Zettl, Director of Immuno-oncology, **Pieris Pharmaceuticals**
Martijn Kelder, Sales Director, **Cergentis**
Maximilian Nitschké, Principal Scientific Researcher, **Genentech**
Melita Irving, Group Leader T-Cell Engineering, **Ludwig Institute for Cancer Research**

Mourad Ferhat, Product Manager for EMEA, **Isoplexis**
Nicolas Mach, Medical Oncologist Professor at Geneva Medical School Head of Clinical Research Unit at the Oncology Division, **Geneva University Hospital**

CSO of MaxiVAX

Nicolas Poirier, Chief Scientific Officer, **OSE ImmunoTherapeutics**
Oliver Hill, Vice President, Drug Discovery, **Apogenix**
Oliver Nussbaumer, Head of Immunology, **GammaDelta Therapeutics**
Omid Vafa, Chief Business Officer, **TeneoBio**
Philip Arlen, President & CEO, **Precision Biologics**
Philip Beer, Visiting Scientist/Consultant Genomicist, **Sanger Institute/NHS**
Roberto De Luca, Head of Therapeutic Antibodies, **Philochem AG**

Rosario Tizzone, EMEA Biopharma Specialist - Genomics, **BioRad**
Stephen Beers, Professor of Immunology and Immunotherapy, **University of Southampton**
Dr Stephen Lock, PhD, Senior Marketing and Market Development Manager, Biopharma EMEA, **SCIEX**
Steve Thorne, CSO, **Western Oncolytics**
Thomas Hach, Executive Director, Patient Engagement Cardiovascular, Renal & Metabolism, **Novartis**
Thomas Huber, Head of Research, **Almirall**
Timo K. van den Berg, Senior Director Immuno Oncology and Professor of Immunotherapy, **ByondisVictor Cervera Carrascon**, Head of Immunology, **TILT Biotherapeutics**

Roy Baynes, Senior Vice President and Head Global Clinical Development, Chief Medical Officer, **Merck Sharp and Dohme**
Russell LaMontagne, President and CEO, **Boston Immune Technologies and Therapeutics**
Sara Colombetti, Global Head of Oncology Discovery Pharmacology, **Roche Innovation Center**
Sari Personen, VP Scientific and Clinical Development, Co-Founder, **Valo Therapeutics**
Sebastian Schlicker, Director Biologics, **Genedata**
Senior representative, **Abzena**
Senior Representative, **Amgen**
Senior Representative, **Genedata**
Sijme Zeilemaker, CEO, **Immunetune**
Sophia Karagiannis, Professor of Translational Cancer Immunology and Immunotherapy, **Kings College London**

Day 1 – Tuesday 9th November

Opening Keynotes

ROOM SYDNEY

9:00am	Welcome from Terrapinn		
9:05am	Chair's opening remarks		
9:10am	Translational Learnings from BCMA and CD19 CAR-T trials Anne Kerber , Senior Vice President, Head Cell Therapy Development, Bristol Myers Squibb (CONFIRMED)		
9:35am	Engineering Better Biologics: Does Nature Know Best? Anne De Groot MD , CEO/CSO, EpiVax (CONFIRMED)		
10:00am	Keynote panel discussion: What does the future of Immunotherapy hold for Oncology and Infectious Diseases? Chair: Hans S. Keirstead , Chief Executive Officer, AIVITA Biomedical, Inc. (CONFIRMED) Christian Klein , Head of Oncology Programmes, Department Head Cancer Immunotherapy, Roche Innovation Center Zurich, Roche Pharma Research and Early Development (CONFIRMED) Jessica Flechtner , Chief Scientific Officer, Genocea Biosciences (CONFIRMED)		
10:40am	Networking Break		
11:30am	Round Tables		
	ROOM SYDNEY		
	<p align="center">Round Table 1</p> <p>Immune cells as biomarkers of response or resistance to antibody immunotherapies</p> <p align="center">OPEN ROUNDTABLE - DELEGATES ARE ENCOURAGED TO DISCUSS AMONG THEMSELVES ON THE TOPIC ABOVE</p>	<p align="center">Round Table 2</p> <p align="center">TNFRSF-Agonists: Is site-specific engagement by multiformats/bi-specific biologics the right strategy?</p> <p align="center">Oliver Hill, Vice President, Drug Discovery, Apogenix (CONFIRMED)</p>	<p align="center">Round Table 3</p> <p>Maggie Cheang, Team Leader, Genomic Analysis – Clinical Trials, Institute of Cancer Research (CONFIRMED)</p>
	<p align="center">Round Table 4</p> <p>Targeting innate immunity in solid cancer therapy</p> <p>Krzysztof Masternak, Director of Drug Discovery, Light Chain Bioscience – A Brand of Novimmune SA (CONFIRMED)</p>	<p align="center">Round Table 5</p> <p>Combination therapies with cell therapies</p> <p>Alain Vertes, Managing Director, NxR Biotechnologies (CONFIRMED)</p>	<p align="center">Round Table 6</p> <p>Selection of immunomodulatory payloads to OV therapeutics</p> <p>Angelica Loskog, CEO, LOKON Pharma (CONFIRMED)</p>
	<p align="center">Round Table 7</p> <p>Gene-engineering and combinatorial therapy approaches for tackling solid tumors</p> <p>Melita Irving, Group Leader T-Cell Engineering, Ludwig Institute for Cancer Research (CONFIRMED)</p>	<p align="center">Round Table 8</p> <p>Jennifer Bolsee, Research & Development Senior Scientist, Celyad Oncology (CONFIRMED)</p>	
12:35pm	Networking Lunch		

	Manufacturing, Commercialisation & Market Access ROOM SHANGHAI 1-2	Cell & Gene Therapy ROOM SHANGHAI 3-4	Innate & Adaptive Checkpoint Inhibition ROOM BOSTON	Oncolytic Viruses ROOM KAIRO
	Chair: Federica Frascchetti , Associate Director, engineering, Large Molecule External Manufacturing, Technical Operations, Merck (CONFIRMED)	Chair: Jessica Flechtner , Chief Scientific Officer, Genocea Biosciences (CONFIRMED)	Chair: Nicolas Poirier , Chief Scientific Officer, OSE ImmunoTherapeutics (CONFIRMED)	Chair: Christophe Queva , CSO, Oncorus (CONFIRMED)
2:00pm	Strategies to improve manufacturing robustness & scale of TCR-T products Ali Mohamed , Vice President CMC, Immatics (CONFIRMED)	T-SiGN tumor reengineering: reprogramming the tumor microenvironment to drive anti-tumor immunity Brian Champion , CSO, PsiOxus Therapeutics (CONFIRMED)	Co-stimulatory single-chain TNFSF ligands as building blocks for bispecific fusion proteins Oliver Hill , Vice President, Drug Discovery, Apogenix (CONFIRMED)	Phase I/II clinical data using LOAd703 in pancreatic cancer Angelica Loskog , CEO, LOKON Pharma (CONFIRMED)
2:20pm	At the interface with Contract Manufacturers: the key for effective relationship management Federica Frascchetti , Associate Director, engineering, Large Molecule External Manufacturing, Technical Operations, Merck (CONFIRMED)	Identification of Novel pHLA Targets to Enable Targeting of Solid Tumors with High Potency Compounds Hanspeter Gerber , CEO and CSO, 3T Biosciences (CONFIRMED)	Multidimensional personalized response assessment to microglia modulators in glioblastoma bioreactors Gregor Hutter , Research Group Leader, University of Basel (CONFIRMED)	Unique cancer and anti-infective immunotherapy platforms Sari Personen , VP Scientific and Clinical Development, Co-Founder, Valo Therapeutics (CONFIRMED)
2:40pm	Designing Tech Transfers for Success <ul style="list-style-type: none"> Develop a clear understanding of process and analytics Select equipment and materials that future proof your process Map a plan for tech transfer and beyond to ensure Clinical and Commercial success Daniel Bright , Senior Global Project Manager, Ferring Pharmaceuticals (CONFIRMED)	Overcoming the most common challenges in cell & gene therapy development using Droplet Digital PCR Rosario Tizzone , EMEA Biopharma Specialist - Genomics, Bio-Rad (CONFIRMED)	Preclinical development of NI-1801, a CD47xMesothelin bispecific antibody to treat solid tumors Krzysztof Masternak , Director of Drug Discovery, Light Chain Bioscience – A Brand of Novimmune SA (CONFIRMED)	Strategies to enhance systemic antitumor immunity elicited by oncolytic viruses Christophe Queva , CSO, Oncorus (CONFIRMED)
3:00pm	Panel discussion: Affordability of cell & gene therapies	Converging synthetic biology and rational combinations for next generation T-cell therapies	Enhancing Efficacy and Safety of 4-1BB Agonism with PRS-343, a Tumor-Targeted Bispecific	

	Lakshmikanth Gandikota , Vice President, Innovation Science and Technology, Biologics and Cell & Gene Therapy Intas Pharmaceuticals (CONFIRMED)	Melita Irving , Group Leader T-Cell Engineering, Ludwig Institute for Cancer Research (CONFIRMED)	Shane Olwill , SVP, Chief Development Officer, Pieris Pharmaceuticals (CONFIRMED)	
3:20pm	Ali Mohamed , Vice President CMC, Immatic (CONFIRMED)	The Rise of the Next Generation of T-cell Engagers Omid Vafa , Chief Business Officer, TeneoBio (CONFIRMED)		
3:40pm	Networking Break			
	Non-Oncology Immunotherapy ROOM SHANGHAI 1-2	Cell & Gene Therapy ROOM SHANGHAI 3-4	Innate & Adaptive Checkpoint Inhibition ROOM BOSTON	Oncolytic Viruses ROOM KAIRO
	Chair: Ahuva Nissim , Professor, William Harvey Research Institute, Queen Mary University (CONFIRMED)	Chair: Hanspeter Gerber , CEO and CSO, 3T Biosciences (CONFIRMED)	Chair: Nicolas Poirier , Chief Scientific Officer, OSE ImmunoTherapeutics (CONFIRMED)	Chair: Christophe Queva , CSO, Oncorus (CONFIRMED)
4:30pm	Oxidative post translational modification (oxPTM) and autoimmune diseases Ahuva Nissim , Professor, William Harvey Research Institute, Queen Mary University (CONFIRMED)	Gene Therapy of Blood Disorders Lakshmikanth Gandikota , Vice President, Innovation Science and Technology, Biologics and Cell & Gene Therapy Intas Pharmaceuticals (CONFIRMED)	The CD47-SIRPα innate immune checkpoint in cancer Timo K. van den Berg , Senior Director Immuno Oncology and Professor of Immunotherapy, Byondis (CONFIRMED)	Viral Backbone and the design of Oncolytic Viral therapies for intravenous delivery Steve Thorne , CSO, Western Oncolytics (CONFIRMED)
4:50pm	Active immunization against a-synuclein for the prevention and treatment of Parkinson's disease and other synucleopathies Jean-Cosme Dodart , SVP, Preclinical R&D, United Neuroscience (CONFIRMED)	Unleashing the Titans: the GEN-011 Neoantigen-targeted Peripheral T cell Therapy for Solid Tumors" Jessica Flechtner , Chief Scientific Officer, Genocea Biosciences (CONFIRMED)	The impact of immune environment on checkpoint blockade Stephen Beers , Professor of Immunology and Immunotherapy, University of Southampton (CONFIRMED)	Development of a T-cell centred oncolytic virus against solid tumors Victor Cervera Carrascon , Head of Immunology, TILT Biotherapeutics (CONFIRMED)
5:10pm	INO-4800 – A DNA based vaccine against COVID-19 Kate Broderick , Senior Vice President and R&D, Inovio Pharmaceuticals (CONFIRMED)	A Proprietary Tumor Filtrating Lymphocytes (TIL) Platform for Treatment of Solid Tumors Igor Bilinsky Chief Operating Officer, Iovance Biotherapeutics (CONFIRMED)	Notch-dependent Myeloid Cell Regulation Maximilian Nitschké , Principal Scientific Researcher, Genentech (CONFIRMED)	

5:30pm		<p>iNKT-based cell therapy for treatment of tumors</p> <p>Eleni Chantzoura, Team Leader – Immune Receptor Discovery, AgenTus Therapeutics (CONFIRMED)</p>	<p>FAP-Activated Prodrugs and Antibody-Drug Conjugates: TME Targeting of Innate Immune Activators</p> <p>Matthew Vincent, VP of Business development & Therapeutic strategy, Avacta (CONFIRMED)</p>	
5:50pm			<p>Neoantigen cancer vaccines based on synthetic linear DNA with a pyroptotic adjuvant synergize with checkpoint inhibitors</p> <p>Sijme Zeilemaker, CEO, Immunetune (CONFIRMED)</p>	
6:10pm	Offsite Networking Drinks			

Day 2 – Wednesday 10th November

Keynotes: Antibodies & Immunotherapy Joint Plenary

ROOM MONTREAL

9:00am	Chair's opening remarks Lamine Mbow, CSO, Arena Pharmaceuticals (CONFIRMED)
9:05am	Novel approaches for antibody cancer immunotherapy Christian Klein, Head of Oncology Programmes, Department Head Cancer Immunotherapy, Roche Innovation Center Zurich, Roche Pharma Research and Early Development (CONFIRMED)
9:30am	Accelerating Novel Immunotherapeutic Modality Discovery through Digitalization Sebastian Schlicker, Head, Operations - Biologics, Genedata (CONFIRMED)
9:55am	PD-1 antibodies either as precision medicine informed monotherapy or combinations are transforming cancer care Roy Baynes, Senior Vice President and Head Global Clinical Development, Chief Medical Officer, Merck Sharp and Dohme (CONFIRMED)
10:20am	Accelerating Biopharma R&D: Merging Automation & Data Management to Enable Collaboration and Innovation Moderator: Jana Hersch, Ph.D, Scientific Account Manager, Genedata Ezio Bonvini, CSO, Macrogenics Soraya Hölper, Project Lead for Portfolio and Strategy, Sanofi Uwe Wittenberg, Director Research Informatics, Merck Alexander Jung, Head of Digitalization Biologicals Development CMC, Boehringer Ingelheim Markus Enzelberger, Partner, Versant Ventures Björn Hüber, Team Leader Data Management, Novartis Henri Kornmann, Director of Biologics Development, Ferring

11:00am Networking Break

	Cell & Gene Therapy ROOM SHANGHAI 1-2	Combination Therapies ROOM SHANGHAI 3-4	Neoantigens & Therapeutic Vaccines ROOM BOSTON
	Chair: Alain Vertes, Managing Director, NxR Biotechnologies (CONFIRMED)	Chair: Russell LaMontagne, President and CEO, Boston Immune Technologies and Therapeutics (CONFIRMED)	Chair: Geoffrey Lynn, CEO & Co-Founder, Avidea Technologies (CONFIRMED)
11:40am	Using allogeneic dendritic cell biology to develop novel cancer immunotherapies Erik Manting, CEO, Immunicum AB (CONFIRMED)	Preclinical models to evaluate potent off-the-shelf combination treatment for T cell redirection against tumors Sara Colombetti, Global Head of Oncology Discovery Pharmacology, Roche Innovation Center (CONFIRMED)	Homocitrullination of lysine residues mediated by MDSCs in the tumour environment makes an excellent target for cancer Immunotherapy Lindy Durrant, Professor of Cancer Immunotherapy, University of Nottingham (CONFIRMED)

12:00pm	The development of Vdelta1 Gamma Delta T cell platforms for use in next generation allogeneic CAR therapies Oliver Nussbaumer , Head of Immunology, GammaDelta Therapeutics (CONFIRMED)	Innovative lab-on-a-chip platform facilitates CAR-T efficacy and off-target assessment in 3D with combination therapy Dr Michele Zagnoni , Reader, University of Strathclyde (CONFIRMED)	Late-stage clinical development of a personalized vaccine platform technology for cancer and COVID-19 Hans S. Keirstead , Chief Executive Officer, AIVITA Biomedical, Inc. (CONFIRMED)	
12:20pm	Analytical Tools to help the production of your Gene Therapy products Dr Stephen Lock , PhD, Senior Marketing and Market Development Manager, Biopharma EMEAI, SCIEX (RESERVED)	Novel approaches to TNF superfamily antagonism Russell LaMontagne , President and CEO, Boston Immune Technologies and Therapeutics (CONFIRMED)	Development of UB-612; the first multipeptide protein/peptide vaccine in clinical trials Farshad Guirakhoo , Chief Scientific Officer, VAXXINITY (CONFIRMED)	
12:40pm		Boosting immunotherapy efficacy with epidrugs in oncology Christophe Le Tourneau , Head, Department of Drug Development & Innovation, Institut Curie (CONFIRMED)		
1:00pm	Networking Lunch			
	Antibodies for Immunotherapy <i>Shared track with the European Antibody Congress</i> ROOM MONTREAL	Cell & Gene Therapy ROOM SHANGHAI 1-2	Combination Therapies ROOM SHANGHAI 3-4	Neoantigens & Therapeutic Vaccines ROOM BOSTON
	Chair: Thomas Schirrmann , CEO, Corat Therapeutics (CONFIRMED)	Chair: Alain Vertes , Managing Director, NxR Biotechnologies (CONFIRMED)	Chair: Russell LaMontagne , President and CEO, Boston Immune Technologies and Therapeutics (CONFIRMED)	Chair: Eric Halioua , President & CEO, PDC*line Pharma (CONFIRMED)
2:20pm	Bispecific anti-PD1/IL7 preclinical evaluation Nicolas Poirier , Chief Scientific Officer, OSE ImmunoTherapeutics (CONFIRMED)	Cell Encapsulation for Cancer Immunotherapy: MVX-2 a cell line for in-vivo sustained production of immunostimulatory Cytokines and therapeutic antibodies Nicolas Mach , Medical Oncologist Professor at Geneva Medical School Head of Clinical Research Unit at the Oncology Division, Geneva University Hospital	Glycoproteomics-Based Liquid Biopsy As a Novel Approach to Identify Checkpoint-Inhibitor Responders and Inform Optimal Drug Choice Klaus Lindpaintner , Chief Scientific Officer and Chief Marketing Officer, InterVenn (CONFIRMED)	Leveraging antibody & T cell immunity with IV administrable glycopeptide cancer vaccines Geoffrey Lynn , CEO & Co-Founder, Avidea Technologies (CONFIRMED)

		CSO of MaxiVAX (CONFIRMED)		
2:40pm	B cells and antibodies in patients with solid tumours Sophia Karagiannis , Professor of Translational Cancer Immunology and Immunotherapy, Kings College London (CONFIRMED)	Leveraging Platform Technologies for Gene Therapies Andy Lewin , Vice President, Business Development, Manufacturing, Oxford Biomedica (CONFIRMED)	Panel discussion: Challenges around combination therapies Moderator: Christophe Le Tourneau , Head, Department of Drug Development & Innovation, Institut Curie (CONFIRMED)	New class of cancer vaccine based on an off-the-shelf Antigen Presenting Cell line (PDC*line) Eric Halioua , President & CEO, PDC*line Pharma (CONFIRMED)
3:00pm	A Platform Approach for Generation of BiSpecific Antibodies for Immunotherapy Jonah Rainey, PhD , VP, Antibody Engineering and Protein Science, AlivaMab Discovery Services (CONFIRMED)	TRuC T cells: Leveraging the potential of the entire TCR in solid tumors Alfonso Quintas , Chief Medical Officer, TCR2 Therapeutics (CONFIRMED)	Stephen Beers , Professor of Immunology and Immunotherapy, University of Southampton (CONFIRMED) Russell LaMontagne , President and CEO, Boston Immune Technologies and Therapeutics (CONFIRMED) Sara Colombetti , Global Head of Oncology Discovery Pharmacology, Roche Innovation Center (CONFIRMED)	Targeting Tumor Neo-epitopes with Therapeutic Monoclonal Antibodies Philip Arlen , President & CEO, Precision Biologics (CONFIRMED)
3:20pm	Title TBA Juliette Trepeau , Researcher in Biology, Pierre Fabre (CONFIRMED)	CYAD-211, a Non-Gene-Edited Allogeneic anti-BCMA CAR T-cell product to treat Relapsed or Refractory Multiple Myeloma Jennifer Bolsee , Research & Development Senior Scientist, Celyad Oncology (CONFIRMED)		

3:40pm	Harnessing innate immunity in cancer therapy Eric Vivier, CSO, Innate Pharma (CONFIRMED)			
4:00pm	Networking Break			
	Antibodies for Immunotherapy <i>Shared track with the European Antibody Congress</i> ROOM MONTREAL	Cell & Gene Therapy ROOM SHANGHAI 1-2	Targeting the Tumour Microenvironment ROOM SHANGHAI 3-4	
	Chair: Thomas Schirrmann, CEO, Corat Therapeutics (CONFIRMED)	Chair: Heinz Laubli, Senior Physician, Medical Oncology, University Hospital Basel (CONFIRMED)	Chair: Dario Neri, CEO & CSO, Philogen (CONFIRMED)	
4:40pm	VHH as building blocks for Immune and tumour cell-targeting Bill Eldridge, CSO, Isogenica (CONFIRMED)	Improving cancer immunotherapy in a sweet way: How glycans can be used as targets for CAR T cell therapy Heinz Laubli, Senior Physician, Medical Oncology, University Hospital Basel (CONFIRMED)	Antibody-cytokine fusions for cancer therapy with “activity-on-demand” Dario Neri, CEO & CSO, Philogen (CONFIRMED)	
5:00pm	Exclusively local IL-12 immunotherapy of brain cancer with a compartment locked fusion cytokine Johannes vom Berg, Group Leader, Institute of Laboratory Animal Science, University of Zurich (CONFIRMED)	Enhancing Therapeutic Efficacy of Cell Therapy in Solid Tumors Jing Zhao, Chief Medical Officer, Refuge Biotech (CONFIRMED)	TNFR2 – a pleiotropic target for cancer immunotherapy Ingrid Teige, VP of Preclinical Research, BioInvent (CONFIRMED)	
5:20pm	A novel Bispecific Antibody Platform that elicits efficient Tumour Lysis with minimal Cytokine release in liquid and solid tumours Harbani Malik, Senior Scientist, Teneobio (CONFIRMED)		Tripokin: tumor targeted delivery of IL2 potentiated by TNF Roberto De Luca, Head of Therapeutic Antibodies, Philochem AG (CONFIRMED)	
5:40pm	Bispecific $\gamma\delta$-T cell engagers for cancer immunotherapy		IgA tot target MDSC in the TME	

	Hans van der Vliet , CSO, Lava Therapeutics (CONFIRMED)		Jeanette Leusen , Associate Professor, Laboratory, Translational Immunology, UMC Utrecht (CONFIRMED)
6:00pm	Onsite Networking Drinks		

Day 3 – Thursday 11 th November											
Keynotes: Precision Immunotherapy & Biomarkers ROOM SYDNEY											
9:00am	Chair's opening remarks Philip Beer , Visiting Scientist/Consultant Genomicist, Sanger Institute/NHS (CONFIRMED)										
9:05am	Patient enrichment strategies to increase the success rate of Immuno-Oncology early clinical trials Bruno Gomes , Global Head of Biomarkers Oncology, Roche (CONFIRMED)										
9:30am	Enabling Precision Medicine In Respiratory and Immunology Daniel Muthas , Head of Data Science and Bioinformatics, Astrazeneca (CONFIRMED)										
9:55am	Humanizing Biosignatures and moving precision medicine beyond Oncology Thomas Hach , Executive Director, Patient Engagement Cardiovascular, Renal & Metabolism, Novartis (CONFIRMED)										
10:20am	Networking Break										
	<table border="1"> <thead> <tr> <th>Antibodies for Immunotherapy <i>Shared track with the European Antibody Congress</i> ROOM SINGAPORE</th> <th>Precision Immunotherapy & Biomarkers ROOM SYDNEY</th> </tr> </thead> <tbody> <tr> <td>Chair: Samuele Cazzamalli, Group Head of Small Molecule Therapeutics, Philochem</td> <td>Chair: Maria Fiammetta Romano, Professor of Biochemistry, University of Naples "Federico II" (CONFIRMED)</td> </tr> <tr> <td>11:10am Complete genetic quality control for antibody, viral vector and ATMP manufacturing with TLA Martijn Kelder, Sales Director, Cergentis (CONFIRMED)</td> <td>Understanding mechanism of action in humans- the importance of translational studies in early phase IO clinical trials Philip Beer, Visiting Scientist/Consultant Genomicist, Sanger Institute/NHS (CONFIRMED)</td> </tr> <tr> <td>11:30am Bispecific DART Molecules: From Bench to the Bedside" Ezio Bonvini, MD, MacroGenics, Inc. (CONFIRMED)</td> <td>Combining magnetic resonance imaging with systemic monocyte phenotype for GBM management. Maria Fiammetta Romano, Associate Professor of Biochemistry, University of Naples "Federico II" (CONFIRMED)</td> </tr> <tr> <td>11:50am New tricks for old targets: Fc-enhanced CTLA-4 and TIGIT mAbs promote optimal T cell activation and improved anti-tumor immunity. Emmanuel Briend, Associate Director Antibody Discovery, Agenus Bio (CONFIRMED)</td> <td>Accelerating the Next Generation of Immune Medicine with Automated and Highly Multiplexed Cellular Proteomics Mourad Ferhat, Product Manager for EMEA, Isoplexis</td> </tr> </tbody> </table>	Antibodies for Immunotherapy <i>Shared track with the European Antibody Congress</i> ROOM SINGAPORE	Precision Immunotherapy & Biomarkers ROOM SYDNEY	Chair: Samuele Cazzamalli , Group Head of Small Molecule Therapeutics, Philochem	Chair: Maria Fiammetta Romano , Professor of Biochemistry, University of Naples "Federico II" (CONFIRMED)	11:10am Complete genetic quality control for antibody, viral vector and ATMP manufacturing with TLA Martijn Kelder , Sales Director, Cergentis (CONFIRMED)	Understanding mechanism of action in humans- the importance of translational studies in early phase IO clinical trials Philip Beer , Visiting Scientist/Consultant Genomicist, Sanger Institute/NHS (CONFIRMED)	11:30am Bispecific DART Molecules: From Bench to the Bedside" Ezio Bonvini , MD, MacroGenics, Inc. (CONFIRMED)	Combining magnetic resonance imaging with systemic monocyte phenotype for GBM management. Maria Fiammetta Romano , Associate Professor of Biochemistry, University of Naples "Federico II" (CONFIRMED)	11:50am New tricks for old targets: Fc-enhanced CTLA-4 and TIGIT mAbs promote optimal T cell activation and improved anti-tumor immunity. Emmanuel Briend , Associate Director Antibody Discovery, Agenus Bio (CONFIRMED)	Accelerating the Next Generation of Immune Medicine with Automated and Highly Multiplexed Cellular Proteomics Mourad Ferhat , Product Manager for EMEA, Isoplexis
Antibodies for Immunotherapy <i>Shared track with the European Antibody Congress</i> ROOM SINGAPORE	Precision Immunotherapy & Biomarkers ROOM SYDNEY										
Chair: Samuele Cazzamalli , Group Head of Small Molecule Therapeutics, Philochem	Chair: Maria Fiammetta Romano , Professor of Biochemistry, University of Naples "Federico II" (CONFIRMED)										
11:10am Complete genetic quality control for antibody, viral vector and ATMP manufacturing with TLA Martijn Kelder , Sales Director, Cergentis (CONFIRMED)	Understanding mechanism of action in humans- the importance of translational studies in early phase IO clinical trials Philip Beer , Visiting Scientist/Consultant Genomicist, Sanger Institute/NHS (CONFIRMED)										
11:30am Bispecific DART Molecules: From Bench to the Bedside" Ezio Bonvini , MD, MacroGenics, Inc. (CONFIRMED)	Combining magnetic resonance imaging with systemic monocyte phenotype for GBM management. Maria Fiammetta Romano , Associate Professor of Biochemistry, University of Naples "Federico II" (CONFIRMED)										
11:50am New tricks for old targets: Fc-enhanced CTLA-4 and TIGIT mAbs promote optimal T cell activation and improved anti-tumor immunity. Emmanuel Briend , Associate Director Antibody Discovery, Agenus Bio (CONFIRMED)	Accelerating the Next Generation of Immune Medicine with Automated and Highly Multiplexed Cellular Proteomics Mourad Ferhat , Product Manager for EMEA, Isoplexis										

12:10pm	<p>Title TBA</p> <p>Marjolein van Egmond, Professor in Oncology and Inflammation, Amsterdam UMC (CONFIRMED)</p>	<p>Circulating tumor DNA as an early on-treatment predictive biomarker for patients with advanced non-small cell lung cancer receiving immune checkpoint inhibitors</p> <p>Ed Schuurin, Professor of Molecular Oncological Pathology, Clinical Scientist in Molecular Pathology, University Medical Center Groningen (UMCG) (CONFIRMED)</p>
12:30pm	<p>No Presentation in this Track</p>	<p>Pros and cons of several trial designs for immunotherapy and the choice of endpoints</p> <p>Maggie Cheang, Team Leader, Genomic Analysis – Clinical Trials, Institute of Cancer Research (CONFIRMED)</p>
12:50pm	<p>Networking Lunch</p>	
	<p>Combined Festival of Biologics plenary session ROOM SINGAPORE</p>	
	<p>Chair: Jacqueline Delmont, Chief Medical Officer, SOMOS</p>	
2:00pm	<p>Antibodies to watch in 2022</p> <p>Janice Reichert, Executive Director, The Antibody Society (CONFIRMED)</p>	
2:00pm	<p>Biosimilars: the International Regulatory Walkthrough</p> <p>Fernando de Mora, Professor of Pharmacology, Universidad Automatica Barcelona (Confirmed)</p>	
2:40pm	<p>Keynote panel discussion: Exploring clinical needs and novel indications</p> <ul style="list-style-type: none"> • Patient stratification and biomarkers • Applying the best antibody treatment from the start • Starting new programs based on patient needs <p>Chair: Anders Pedersen, Medical Lead in Global Clinical Development, Almirall (CONFIRMED) Thomas Hach, Executive Director, Patient Engagement Cardiovascular, Renal & Metabolism, Novartis (CONFIRMED) Dario Neri, Professor of Chemistry and Applied Biology, Swiss Federal Institute of Technology Zurich (CONFIRMED)</p>	
3:20pm	<p>End of Conference – see you next year!</p>	

**FESTIVAL OF
BIOLOGICS**



Celebrating 15 years of Biosimilars in Europe

World Biosimilar Congress

Basel Congress Center, 9th-11th November 2021

Advisory Board:

Alain Beck, Senior Director, Biologics CMC and Developability, **Pierre Fabre and Associate Editor, mAbs**

Cecil Nick, Vice President Biotechnology, **PAREXEL**

Matthew Turner, Senior Director Government Affairs, **Fresenius Kabi**

Confirmed speakers

Alix Dubes, Senior Director Patent Attorney, **Fresenius Kabi**
Alessandro Slama, General Manager and Senior Director EMEA, **US Pharmacopeia**
Ana Hidalgo-Simon, Biosimilars Lead, **EMA**
Anders Pedersen, Medical Lead in Global Clinical Development, **Almirall**
Andreu Soldevila, CEO, **Syna Therapeutics**
Andrew Roberts, Chief Portfolio Officer, **Alvotech**
Andrew Spiegel, Executive Director, **Global Colon Cancer Association**
Antonella Cardone, Director, **European Cancer Patients Coalition**
Anurag Rathore, Professor, Department of Chemical Engineering, **Indian Institute of Technology, Delhi**
Arnold Walter Schramm, Senior Expert, **Boehringer Ingelheim**
Bert E. Thomas, Senior Vice President, Business Development, **Bio-Thera Solutions**
Caroline Boulliat, Former Head of Biosimilars UK and Ireland, **Amgen**
Cecil Nick, Vice President Biotechnology, **PAREXEL**
Christopher Webster, Principal, **BioApprovals**
David Lancaster, Partner, **Pinsent Masons LLP**
Demet Gol, Global Commercial Execution Lead, Biosimilars, **Amgen**
Fredrik Sundberg, Global Director, Strategic Technology Partnership, **Cytiva**
Gregory Friberg, Vice President of Medical Affairs ELMAC, **Amgen**
Gordon Humphreys, Chairperson of the First Board and Third Board of Appeal, **EUIPO**
Hanmant Barkate, Senior Vice President and Head, Global Medical Affairs, **Glenmark Pharmaceuticals**
Isabel del Rio, Deputy Director, **BIOSIM Spanish Association of Biosimilars**
Isabell Remus, Head, Biopharmaceuticals Europe, **Sandoz**
Jenny Hao, Pharma Operating Partner, **Convergence Partners AG**
Joseph McClellan, Chief Scientific Officer, **Alvotech**
Julie Marechal-Jamil, Director Biosimilar Policy & Science, **Medicines for Europe**
Kalveer Flora, Lead Rheumatology & Biosimilars Specialist Pharmacist, **NHS**
Kathryn Brown, Intermin Vice President for Pharmacy, **Kaiser Permanente**
Kawaldip Sehmi, CEO, **International Alliance of Patients' Organisations**
Marcin Czech, Professor and head of the Department of Pharmacoeconomics, **Institute of Mother and Child Warsaw**
Mark Levick, CEO, **Alvotech**
Marta Baldrighi, Policy and Sciences Officer, **Medicines for Europe**
Martin Perry, Consultant Physician & Rheumatologist, **NHS Greater Glasgow and Clyde**
Michael Muenzberg, Regional Director Medical Affairs Europe/Canada Biosimilars, **Organon**
Mohamed Khater, Director of Medical Affairs, **Samsung Bioepis**

Naime Yurtseven, Head of Facilities & Engineering Basel Biotech Drug Substance Manufacturing, **Roche**
Ned Pojskic, Leader, Pharmacy and Health Provider Relations, **Greenshield Insurance Brokers LLC**
Omar Ali, Visiting Lecturer VBA & Former Adviser to **NICE**, Head of Payers, **Verpora**
Peter Jorgensen, Chief Executive Officer, **Danish Generic and Biosimilar Medicines Industry Association (IGL)**
Philip Schneider, Chair International Advisory Board, **Alliance for Safe Biologic Medicines**
Ping Cao, VP of Business Development, **Shanghai Henlius**
Roman Draï, Research & Development Director, **GEROPHARM**
Sameer Awsare, Managing Director, **Kaiser Permanente**
Sarfaz K. Niazi, Professor of Pharmaceutical Sciences, **University of Illinois**
Sophia Humphreys, Director, System Pharmacy Clinical Services, **Providence St Joseph Health**
Sundar Ramanan, SVP Strategic Operations, **Just - Evotec Biologics**
Tiago Rocca, Strategic Partnerships and Business Development Manager, **Instituto Butantan**
Tibor Anderlei, Director of Sales and Business Development, **Adolf Kuhner**
Tim Shea, Director, **Sterne Kessler Goldstein and Fox Plc**
Tudor Arvinte, Chairman, CEO, **Therapeomic**
Ylenia Ingrassiotta, Senior Pharmacoepidemiologist, **University of Messina**
Vijay Ram Reddy, Senior Director of Global Market Access Strategy, **Biocon**

Day 1 - Tuesday 9th November

Opening Keynotes

ROOM DELHI

09:00	Welcome from Terrapinn		
09:05	Chair's opening remarks Andrew Roberts , Chief Portfolio Officer, Alvotek (Confirmed)		
09:10	15 years of biosimilars in Europe – current challenges and opportunities <ul style="list-style-type: none"> • Uptake and access • Identifiability and safety • International collaboration to move forward Ana Hidalgo-Simon , Biosimilars Lead, EMA (Confirmed)		
09:30	Commercialisation and Access Learnings from 15 Years of Biosimilars in Europe Caroline Boulliat , Former Head of Biosimilars UK and Ireland, Amgen (Confirmed)		
09:50	Keynote Panel Discussion: Regulatory lessons learnt from the past 15 years and what can regulatory guidelines do to improve access going forward? Chair: Philip Schneider , Chair International Advisory Board, Alliance for Safe Biologic Medicines (Confirmed) <ul style="list-style-type: none"> • Ana Hidalgo-Simon, Head of Advanced Therapies, EMA (Confirmed) • Caroline Boulliat, Former Head of Biosimilars UK and Ireland, Amgen (Confirmed) • Marta Baldrighi, Policy and Sciences Officer, Medicines for Europe (Confirmed) 		
10:40	Networking break Roundtable discussion session ROOM DELHI <i>There will be one rotation, after 30 minutes, with 5 minutes to change over</i>		
	TABLE 1 Pricing and Reimbursement Models to Promote Uptake	TABLE 2 Biosimilars in Oncology Andrew Spiegel , Executive Director, Global Colon Cancer Association (Confirmed)	TABLE 3 Accelerating Development of Biosimilars: Current Bioprocessing Challenges and Opportunities Fredrik Sundberg , Global Director, Strategic Technology Partnership, Cytiva (Confirmed)
	TABLE 4	TABLE 5 IP and Legal Considerations for Biosimilars	TABLE 6 Challenges with Commercialising Biosimilars

	Is Global Regulatory Interaction on Biosimilars Needed?		
12:35	Networking lunch		
	Track 1 Commercialisation and Market Access ROOM DELHI	Track 2 Manufacturing, Analysis, Research and Development ROOM DARWIN	
	Chair: Steven Lehrer , Senior Management Advisor, SBLehrer LLC	Chair: Alain Beck , Senior Director, Biologics CMC and Developability, Pierre Fabre and Associate Editor, mAbs	
2:00	The challenges of global commercialisation for a biosimilars player Jenny Hao , Pharma Operating Partner, Convergence Partners AG (Confirmed)	Aggregates formation after mixing biopharmaceuticals with human plasma and blood: comparison of originator and biosimilar products Tudor Arvinte , Chairman, CEO, Therapeomic (Confirmed)	
2:20	Biosimilars in Denmark. High Uptake and Low Prices. What's the Story? <ul style="list-style-type: none"> • Belief in Science • Health Authorities • Procurements, tenders and pricing • Stakeholder participation • Information to patients • A miracle-or just common sense and cooperation? Peter Jorgensen , Chief Executive Officer, Danish Generic and Biosimilar Medicines Industry Association (IGL) (Confirmed)	State-of-the-art analytical methods for originator and biosimilar characterization <ul style="list-style-type: none"> • Critical Quality Attributes ranking • Multi-dimensional analytical workflows • Multi-level mAbs and Fc-fusion proteins characterization Alain Beck , Senior Director, Biologics CMC and Developability, Pierre Fabre and Associate Editor, mAbs (Confirmed)	
2:40	Value Based Agreements and Biosimilars - innovative contracting and new payer perspectives with biosimilars <ul style="list-style-type: none"> • Payer trends and global drivers for innovative contracting • Uptake of biosimilars and payer strategies for successful implementation • New tactics and drivers from branded parent innovators and payer offerings on value trade offs • VBA & biosimilars - case examples Omar Ali , Visiting Lecturer VBA & Former Adviser to NICE, Head of Payers, Verpora (Confirmed)	Fast Scale Up of Your Shake Flask Results <ul style="list-style-type: none"> • Support analyzing the shake flask conditions • Presenting scale up examples Tibor Anderlei , Director of Sales and Business Development, Adolf Kuhner (Confirmed)	
3:00	Access & VBC strategy to enable the acceleration of Biosimilar Commercialisation	Process Control in Continuous Manufacturing	

	Vijay Ram Reddy , Senior Director of Global Market Access Strategy, Biocon Biologics (Confirmed)	<ul style="list-style-type: none"> • Novel strategies for effective control of continuous processes. • Statistical process control and monitoring of protein refolding, from buffer preparation to refold quenching. • Traditional offline HPLC for online analysis using a 2 way/6 port valve to facilitate simultaneous automate sampling of product stream eluting form a process column and fractionation. • A single NIR flow cell used before the inlet of the loading column to measure the concentration of mAb in the harvested broth. <p>Anurag Rathore, Professor, Department of Chemical Engineering, Indian Institute of Technology, Delhi</p>
3:20		<p>US Pharmacopeia Biological Performance Standards</p> <ul style="list-style-type: none"> • Brief history of USP • Biologics analytical testing • mAb PS <p>Alessandro Slama, General Manager and Senior Director EMEA, US Pharmacopeia (Confirmed)</p>
3:40	Afternoon refreshments	
	Commercialisation and Market Access ROOM DELHI	Manufacturing, Analysis, Research and Development ROOM DARWIN
4.30	<p>The role of biosimilars in the Polish reimbursement system</p> <ul style="list-style-type: none"> • P&R decision making in Poland • Biosimilar status and importance • Examples, benefits and challenges <p>Marcin Czech, Professor and head of the Department of Pharmacoeconomics, Institute of Mother and Child Warsaw (Confirmed)</p>	<p>What is enough in the development of biosimilars?</p> <ul style="list-style-type: none"> • Cost effective development of Biosimilars • Orthogonal characterisation of biologics • Biosimilarity assessment <p>Andreu Soldevila, CEO, Syna Therapeutics (Confirmed)</p>
4:50	<p>Biosimilars in Canada – Public and Private Drug Plan Developments</p> <ul style="list-style-type: none"> • Biosimilars have been approved in Canada since 2015 • Dozens of biosimilars have been approved, with amrket uptake varying significantly by molecule • This talk will explore recent trends in biosimilar uptake including efforts by provincial governments to mandate biosimilar transitioning • Recently approved Adalimumab biosimilar dynamics will be explored 	<p>Fireside Chat: The importance of clinical streamlining and how to achieve this.</p> <ul style="list-style-type: none"> • Andreu Soldevila, CEO, Syna Therapeutics (Confirmed) • Alain Beck, Senior Director, Biologics CMC and Developability, Pierre Fabre and Associate Editor, mAbs (Confirmed)

	Ned Pojskic , Leader, Pharmacy and Health Provider Relations, Greenshield Insurance Brokers LLC	
5:10	Panel Discussion: Opportunities and Challenges for Biosimilar Uptake Across Europe	
5:30	<ul style="list-style-type: none"> • Vijay Ram Reddy, Senior Director of Global Market Access Strategy, Biocon Biologics (Confirmed) • Peter Jorgensen, Chief Executive Officer, Danish Generic and Biosimilar Medicines Industry Association (IGL) (Confirmed) • Demet Gol, Global Commercial Execution Lead, Biosimilars, Amgen (Confirmed) 	
5:50		
6:10	Offsite Drinks Reception	

Day 2 – Wednesday 10th November			
Opening Keynotes			
ROOM DELHI			
9:00	Chair's opening remarks Chair: Antonella Cardone , Director, European Cancer Patients Coalition		
9:05	Opening Keynote presentation: Development and Validation of a GMP SPR-assay for measuring relative potency of a Therapeutic Antibody <ul style="list-style-type: none"> • For three decades, the SPR technology is applied at Boehringer Ingelheim supporting drug development of Biopharmaceutical products. The talk will introduce the Boehringer Ingelheim Analytical Development Biologicals Department (ADB) and discuss how SPR technology can support Biopharmaceutical Development in a GMP environment. • A case study discussing the development and the commercial validation of a robust and QC-suitable SPR-based relative potency assay for release and stability testing of a therapeutic antibody under GMP. Arnold Walter Schramm , Senior Expert, Boehringer Ingelheim		
09:30	The Evolution of the Regulatory Biosimilar Pathway <ul style="list-style-type: none"> • Development of regulatory requirements for biosimilar approval in Europe and the US • Current hot topics in enabling further streamlining biosimilar development • Outlook to the future Martin Schiestl , Global Head of Regulatory Affairs Policy, Sandoz (Confirmed)		
9:55	Keynote Fireside Chat: Promoting Equitable Access of Biosimilars across therapeutic areas Andrew Spiegel , Executive Director, Global Colon Cancer Association (Confirmed) and Sundar Ramanan , SVP Strategic Operations, Just - Evotec Biologics (Confirmed)		
10:35	Keynote Presentation: The Sustainable Future of Biosimilars Mark Levick , Chief Executive Officer, Alvotech		
10:55	Networking break		
	<table border="0" style="width: 100%;"> <tr> <td style="width: 50%; text-align: center;"> Track 1 Regulation and Policy ROOM DELHI </td> <td style="width: 50%; text-align: center;"> Track 2 Sustainability ROOM DARWIN </td> </tr> </table>	Track 1 Regulation and Policy ROOM DELHI	Track 2 Sustainability ROOM DARWIN
Track 1 Regulation and Policy ROOM DELHI	Track 2 Sustainability ROOM DARWIN		
	<table border="0" style="width: 100%;"> <tr> <td style="width: 50%;"> Chair: Marta Baldrighi, Policy and Sciences Officer, Medicines for Europe </td> <td style="width: 50%;"> Chair: Philip Schneider, Chair International Advisory Board, Alliance for Safe Biologic Medicines (Confirmed) </td> </tr> </table>	Chair: Marta Baldrighi , Policy and Sciences Officer, Medicines for Europe	Chair: Philip Schneider , Chair International Advisory Board, Alliance for Safe Biologic Medicines (Confirmed)
Chair: Marta Baldrighi , Policy and Sciences Officer, Medicines for Europe	Chair: Philip Schneider , Chair International Advisory Board, Alliance for Safe Biologic Medicines (Confirmed)		

11.30	<p>The WHO SBP guideline revision: a chance to build on experience to achieve a more efficient regulatory landscape</p> <ul style="list-style-type: none"> • The WHO is currently revising its Similar Biotherapeutics Products (i.e. biosimilar medicines) guidelines, which were first published in 2009. The input of biosimilar medicines manufacturers will be essential in ensuring fit-for-purpose guidance. • This important revision happens as discussions are intensifying worldwide on how to achieve regulatory streamlining. Among the necessary steps to reach this goal, embracing regulatory science advances, increased international convergence among regulators, and a concerted global roadmap for implementation of clinical trial tailoring will be key. • The role of the WHO in achieving a more efficient regulatory landscape for biosimilar medicines spans beyond standard setting and guidance issuance. <p>Marta Baldrighi, Policy and Sciences Officer, Medicines for Europe</p>	<p>Clinical Efficacy Testing of Biosimilars is not Necessary--an FDA perspective?</p> <ul style="list-style-type: none"> • Is it possible to design a meaningful clinical efficacy testing for biosimilars? • Does the history of clinical efficacy testing support biosimilarity claims beyond what is already established? • Is indication extrapolation possible if clinical efficacy is required for approval of biosimilars? <p>Sarfaraz K. Niazi, Professor of Pharmaceutical Sciences, University of Illinois (Confirmed)</p>
11.50	<p>Global policies enabling access through substitution</p> <p>Joseph McClellan, Chief Scientific Officer, Alvotech (Confirmed)</p>	<p>Fostering sustainable access to biosimilars</p> <ul style="list-style-type: none"> • How to support biologic competition and reinvestment in healthcare? • What can we learn from front runners: Key differentiation & success factors in biosimilar policy? • Emerging challenges: Healthcare system makeover and better patient care <p>Julie Marechal-Jamil, Director Biosimilar Policy & Science, Medicines for Europe (Confirmed)</p>
12.10	<p>Novel Regulatory Strategies for Biosimilars and Validation Guideline Review</p> <ul style="list-style-type: none"> • Points-to-consider for compliance when validating advanced analytics. 	<p>Implementing Biosimilars and the Role of Specialist Pharmacists</p>

	<ul style="list-style-type: none"> Review of the world's first SPR Assay Validation Guideline for potency assays. Industry case-study: Novel validation approach for comparability assessment and QC. <p>Fredrik Sundberg, Global Director, Strategic Technology Partnership, Cytiva (Confirmed)</p>	<p>Kalveer Flora, Lead Rheumatology & Biosimilars Specialist Pharmacist, NHS (Confirmed)</p>
12.30	<p>Evidentiary Consistency and Regulatory Efficiency in Development of Biosimilars</p> <ul style="list-style-type: none"> The endpoint of comparability is the critical indistinguishability of the clinical properties of the compared products. To be efficient, regulators should apply consistent evidentiary requirements and logic to both biosimilars and manufacturing changes of all biologics. Approval of biosimilars through regulatory reliance is a logical outcome that would enhance regulatory efficiency and access for patients. <p>Christopher Webster, Principal, BioApprovals (Confirmed)</p>	<p>Sustaining Uptake in Rheumatology Biosimilars</p> <p>Sundar Ramanan, SVP Strategic Operations, Just - Evotec Biologics (Confirmed)</p>
12:50	Networking lunch	
	<p>Biosimilars in Oncology ROOM DELHI</p>	<p>Emerging Regions Virtual Session ROOM SAMARKAND</p>
	Chair: Andrew Spiegel , Executive Director, Global Colon Cancer Association	Chair: TBD
2.20	<p>Biosimilars: Improving patient access and the sustainability of healthcare systems</p> <ul style="list-style-type: none"> Biosimilar cancer medicines present a necessary and timely opportunity for patients in Europe. They may increase access to medicines by improving the financial sustainability of our healthcare systems. Increased availability of effective biosimilars translates directly into driving down the costs of biological medicines as the market becomes more competitive and potentially allowing more 	<p>Biosimilar Breakthrough: China to Global</p> <ul style="list-style-type: none"> Quality by design Globalisation strategy China's journey of globalisation <p>Ping Cao, VP of Business Development, Shanghai Henlius (Confirmed)</p>

	<p>cancer patients to access the medicines they need</p> <ul style="list-style-type: none"> • The switching and substitution still present a challenge, and we strongly believe that patients must have an active role in the decision-making concerning their treatment. It is important to highlight that patients must be prescribed the safest and most efficacious treatment possible and be closely monitored at all times. <p>Antonella Cardone, Director, European Cancer Patients Coalition (Confirmed)</p>	
2.40	<p>Innovative Biosimilars Adoption Strategies and post COVID-19 Healthcare Recovery</p> <ul style="list-style-type: none"> • COVID-19 has caused a serious global public health and economic crisis. • Large molecule biologic medications are the driving force behind high drug costs. Innovative formulary management can help reduce drug costs without compromising patient care. • Biosimilar products are highly similar to brand name biologics and are a fraction of the cost. 100 billion dollars can potentially be saved via the utilization of biosimilars. Thus, biosimilars can help alleviate financial burdens during this challenging time. <p>Sophia Humphreys, Director, System Pharmacy Clinical Services, Providence St Joseph Health (Confirmed)</p>	<p>From Unknown Biosimilar Developer to Biosimilar Partner of Choice</p> <p>Bert E. Thomas, Senior Vice President, Business Development, Bio-Thera Solutions (Confirmed)</p>
3.00	<p>Problems with pharmacovigilance programs: an opportunity for improvement</p> <p>Philip Schneider, Chair International Advisory Board, Alliance for Safe Biologics Medicines (Confirmed)</p>	<p>Biosimilars in Brazil</p> <p>Tiago Rocca, Strategic Partnerships and Business Development Manager, Instituto Butantan, Government of Brazil (Confirmed)</p>
3.20	<p>Panel Discussion: Creating a sustainable future for Biosimilars</p> <p>Chair: Philip Schneider, Chair International Advisory Board, Alliance for Safe Biologic Medicines (Confirmed)</p>	

	<ul style="list-style-type: none"> • Matthew Turner, Senior Director Government Affairs, Fresenius Kabi (Confirmed) • Isabell Remus, Head, Biopharmaceuticals Europe, Sandoz (Confirmed) • Michael Muenzberg, Regional Director Medical Affairs Europe/Canada Biosimilars, Organon (Confirmed) <ul style="list-style-type: none"> • What is the impact of single-tender contracting on sustainability in the biosimilars market? • What is the impact of non-medical switching policies on sustainability in the biosimilars market? • How do you balance the need to manage the cost of medicines and the need to provide financial incentives to enter and remain in the market? 	
4:00	Networking break	
	Biosimilars in Oncology and Real World Evidence	
	ROOM DELHI	
	Chair: Andrew Spiegel , Executive Director, Global Colon Cancer Association	
4.30	Biosimilars clinical evidence and lessons learned	
	<ul style="list-style-type: none"> • Clinical evidence of Biosimilars • Samsung Bioepis success stories, lessons learned • Landscaping the future of Biosimilars 	
	Mohamed Khater , Director of Medical Affairs, Samsung Bioepis (Confirmed)	
4:50	A Clinician's Guide to Biosimilars in Oncology	
	<ul style="list-style-type: none"> • Biosimilars in oncology: <ul style="list-style-type: none"> - Key therapeutic options for cancer treatment <ul style="list-style-type: none"> • Extrapolation data to other Indications: - Scientific rationale, Regulatory Guidelines, Case studies <ul style="list-style-type: none"> • Interchangeability, Switching, Substitution: - Scientific rationale, Regulatory Guidelines 	

	Dr Hanmant Barkate , Senior Vice President and Head of Global Medical Affairs, Glenmark Pharmaceuticals (Confirmed)
5:10	Fireside Chat: The importance of Biosimilars in Oncology Andrew Spiegel , Executive Director, Global Colon Cancer Association (Confirmed) and Antonella Cardone , Director, European Cancer Patients Coalition (Confirmed)
5:50	Biosimilars: clinical data requirements-have the regulators got it right? <ul style="list-style-type: none"> • Residual uncertainty after demonstrating similarity at the structural and biological activity level. • Are studies in patients needed? • What concerns are addressed by patient data. • The position of different regulatory agencies. Cecil Nick , Vice President Biotechnology, PAREXEL (Confirmed)
6:10	Onsite Drinks Reception – Sponsored by Celonic

Day 3 – Thursday 11th November	
Opening Keynotes ROOM DELHI	
09.00	Chair’s Opening Remarks:
09.05	Drug Company EU Trademark and Design Disputes Gordon Humphreys , Chairperson of the First Board and Third Board of Appeal, EUIPO (Confirmed)
09.20	African Medicines Agency and Patient Engagement in Biosimilar Regulations <ul style="list-style-type: none"> • Improving Biosimilars Access, Safety, Quality and Equity in Africa Kawaldip Sehmi , CEO, International Alliance of Patients' Organisations (Confirmed)
09.45	Keynote Fireside Chat: Building Resiliency in the Biosimilar Market Place Vijay Ram Reddy , Senior Director of Global Market Access Strategy, Biocon (Confirmed) Gregory Friberg , Vice President Medical Affairs ELMAC , Amgen (Confirmed)
10:25	Networking break
	Track 1 Biosimilars in the Clinical Setting: Education, Physician Engagement and Pricing
	Track 2 IP and Legal

	Models ROOM DELHI	ROOM DARWIN
	Chair: Naime Yurtseven , Head of Facilities & Engineering Basel Biotech Drug Substance Manufacturing, Roche	Chair: Tim Shea , Director, Sterne Kessler Goldstein and Fox Plc
10.50	<p>Interchangeability and extrapolation in biosimilars: lessons learnt from original biologics</p> <p>Fernando de Mora, Professor of Pharmacology, Universidad Automatica Barcelona (Confirmed)</p>	<p>The VALORE Project</p> <ul style="list-style-type: none"> The VALORE project multi-database network has access to data on more than 140,000 biological drug users with immune-mediated inflammatory diseases (with a cumulative exposure of 507,745 person-years during the entire follow-up) from 13 Italian regions. Overall, the cumulated amount of person-time of exposure to biological drugs approved for immune-mediated inflammatory diseases provides enough statistical power to investigate weak, moderate, and strong associations of almost all individual biological drugs and the most clinically relevant safety outcomes. This distributed database network captured data on a large number of etanercept, adalimumab, and infliximab users who switched between originator and biosimilar during the entire follow-up, thus offering the opportunity to investigate interchangeability in a real-world setting. <p>Ylenia Ingrasciotta, Senior Pharmacoepidemiologist, University of Messina (Confirmed)</p>
11.10	<p>Learnings from 15 years of biosimilars: How to effectively educate HCPs and patients in new therapeutic areas</p> <ul style="list-style-type: none"> Biosimilar misinformation and disparagement is a fact The need for education about biologics including biosimilars is still significant, and will be critical for the uptake in new therapeutic areas Effective education around biologics including biosimilars has to address all stakeholders in a tailored manner <p>Michael Wiechmann, Global Head of Medical Affairs, Biopharmaceuticals, Sandoz (Confirmed)</p>	<p>Key Legal Developments in US Biosimilars 2021</p> <p>Tim Shea, Director, Sterne Kessler Goldstein and Fox Plc (CONFIRMED)</p>
11.30	<p>A short glance of biosimilars in Spain</p> <ul style="list-style-type: none"> Spanish biosimilar market: some figures Economic impact of biosimilars in Spain A proposal on Gain-sharing schemes <p>Isabel del Rio, Deputy Director, BIOSIM Spanish Association of Biosimilars</p>	<p>Panel Discussion: How to bypass legal challenges and bring a biosimilar to market</p> <ul style="list-style-type: none"> - Alix Dubes, Senior Director Patent Attorney, Fresenius Kabi (Confirmed) - David Lancaster, Partner, Pinsent Masons (Confirmed) - Brenda Panichi, Senior Patent Counsel, Abbott (Confirmed)

	(Confirmed)	
11.50	<p>Successful uptake of biosimilars in Kaiser Permanente</p> <p>Dr Sameer Asware, Managing Director, Kaiser Permanente and Kathryn Brown, Interim Vice President for Pharmacy, Kaiser Permanente (Confirmed)</p>	Moderator: Tim Shea , Director, Sterne Kessler Goldstein and Fox Plc (Confirmed)
12.10	<p>Pandemic changes in biosimilar use: where are we now?</p> <p>Martin Perry, Consultant Physician & Rheumatologist, NHS Great Glasgow and Clyde (Confirmed)</p>	
12.30	<p>Uplift Primary Care: Building a Path for Success: "The Grassroots Movement to Re-Design Healthcare"</p> <p>Jason Helgerson, Founder and Chief Executive Officer, Helgerson Solutions Group (CONFIRMED)</p>	
12:50	Networking lunch	
	Festival of Biologics Basel Concluding Presentations	
	ROOM SINGAPORE	
	Chair: Jacqueline Delmont , Chief Medical Officer, SOMOS	
2.00	<p>Antibodies to watch in 2022</p> <p>Janice Reichert, Executive Director, The Antibody Society (CONFIRMED)</p>	
2.20	<p>Biosimilars: from science to market dynamics</p> <p>Fernando de Mora, Professor of Pharmacology, Universidad Automatica Barcelona (CONFIRMED)</p>	

2.40	<p>Keynote panel discussion: Exploring clinical needs and novel indications</p> <ul style="list-style-type: none">• Patient stratification and biomarkers• Applying the best antibody treatment from the start• Starting new programs based on patient needs <p>Chair: Anders Pedersen, Medical Lead in Global Clinical Development, Almirall (CONFIRMED) Thomas Hach, Executive Director, Patient Engagement Cardiovascular, Renal & Metabolism, Novartis (CONFIRMED) Dario Neri, Professor of Chemistry and Applied Biology, Swiss Federal Institute of Technology Zurich (CONFIRMED)</p>
3:20	Thank you and see you next year!

